A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients With Moderate-to-Severe Chronic Kidney Disease and Uncontrolled Hypertension
Phase: PHASE2
Conditions: Chronic Kidney Diseases, Hypertension
Sponsor: KBP Biosciences

Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
1
 
 
CLINICAL STUDY PROTOCOL 
 
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 
Multi-Center Study to Assess the Efficacy, Safety, and 
Pharmacokinetics of KBP-5074 in Patients with Moderate-to-Severe 
Chronic Kidney Disease and Uncontrolled 
Hypertension – (BLOCK/CKD) 
 
Investigational Product: KBP-5074 
Protocol Number: KBP5074-2-001 
EudraCT Number: 2019-001579-35 
 
Sponsor: 
KBP BioSciences Co., Ltd. 
116 Village Blvd, Suite 210 
Princeton, NJ 08540 
United States 
Telephone: 609-531-0889 
Fax: 609-531-0892 
 
 
Original Protocol: 14 February 2018 
Amendment 1: 02 May 2018 
Amendment 2: 05 April 2019 
 
 
Confidentiality Statement 
The information in this document is confidential and is not to be disclosed without the written 
consent of KBP BioSciences Co., Ltd. except to the extent that disclosure would be required by 
law and for the purpose of evaluating and/or conducting a clinical study for KBP BioSciences 
Co., Ltd. You are allowed to disclose the contents of this document only to your Institutional 
Review Board or Independent Ethics Committee and study personnel directly involved with 
conducting this protocol. Persons to whom the information is disclosed must be informed that the 
information is confidential and proprietary to KBP BioSciences Co., Ltd. and that it may not be 
further disclosed to third parties. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
2
SIGNATURE PAGE 
STUDY TITLE: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center 
Study to Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients with 
Moderate-to-Severe Chronic Kidney Disease and Uncontrolled 
Hypertension – (BLOCK/CKD) 
 
We, the undersigned, have read this protocol and agree that it contains all necessary information 
required to conduct the study. 
Signature 
 
 
 
 
 
 
 
Date 
  
 
 
 
April 16, 2019 
 
Daniel J. Wilson, MD, FACP, FCCP 
Senior Vice-President, Clinical Development 
KBP BioSciences Co., Ltd. 
  
 
 
 
 
 
April 16, 2019 
 
 
Vincent J. Benn, PhD, MBA 
Vice President, Regulatory and Medical Affairs 
KBP BioSciences Co., Ltd.  

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
3
INVESTIGATOR AGREEMENT 
By signing below I agree that: 
I have read this protocol. I approve this document and I agree that it contains all necessary details 
for carrying out the study as described. I will conduct this study in accordance with the design and 
specific provision of this protocol and will make a reasonable effort to complete the study within 
the time designated. I will provide copies of this protocol and access to all information furnished 
by KBP BioSciences Co., Ltd. to study personnel under my supervision. I will discuss this material 
with them to ensure they are fully informed about the study product and study procedures. I will 
let them know that this information is confidential and proprietary to KBP BioSciences Co., Ltd. 
and that it may not be further disclosed to third parties. I understand that the study may be 
terminated, or enrollment suspended at any time by KBP BioSciences Co., Ltd., with or without 
cause, or by me if it becomes necessary to protect the best interests of the study patients at my site. 
I agree to conduct this study in full accordance with Food and Drug Administration Regulations, 
Institutional Review Board/Independent Ethics Committee Regulations and International Council 
for Harmonisation Guidelines for Good Clinical Practices. 
 
 
 
 
 
 
______________________________________________  
____________________ 
Investigator’s Signature 
 
 
 
 
 
Date 
 
 
 
______________________________________________ 
Investigator’s Printed Name 
 
  
 
 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
4
Summary of Changes – Amendment 2 
The protocol was amended due to change in contract research organization and feedback from 
Investigators to ensure continued recruitment of subjects.   
Specific changes include (bolded text reflects new wording; strikethrough text indicates deleted 
wording): 
1. Sponsor signatory changed to reflect changes in personnel. 
2. Medpace Reference Laboratory and Medpace changed to ‘central laboratory’ and Worldwide 
Clinical Trials, as appropriate, throughout the protocol to reflect a change in Contract 
Research Organization involved with the study. 
3. Indication, Objectives, and Study Population in the Synopsis clarified to meet the European 
Society of Cardiology (ESC)/European Society of Hypertension (ESH) guidelines for Grade 
1 or 2 systolic hypertension.  
4. Study design in the Synopsis and Section 3 updated to reflect current protocol. 
Original Wording: 
Added new paragraph and updated as noted below. 
Amended Wording: 
Serum potassium levels, serum creatinine, and blood pressure will be monitored 
throughout the study and clinically significant changes will be reported as adverse 
events of special interest. 
At Screening and the end of the placebo run-in period (Visit 3), patients must have 
uncontrolled hypertension (Grade 1 to 2 systolic hypertension – ESC/ESH), defined as 
resting trough-cuff seated SBP  140 and  179 mmHg, based on the mean of at least 2 
current consecutive blood pressure readings in the clinic, a serum potassium 
 4.8 mmol/L at Screening and the end of the placebo run-in period (Visit 3), and a mean 
(Visit 1 and Visit 3) eGFR  15 and  44 mL/min/1.73 m2. 
5. Sites changed to reflect identification of actual study sites: 
Original Wording: 
Approximately 60 sites in the United States, Mexico, Israel, Australia, Chile, and 
Argentina. 
Amended Wording: 
Approximately 60 90 sites in the United States, Mexico, North America, South America, 
Israel, Australia, Chile, and Argentina and Europe. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
5
6. Inclusion and exclusion criteria updated in Sections 4.1 and 4.2 to reflection current practices 
and uncontrolled hypertension definition of ESC/ESH.  
Original Wording: 
Updated Inclusion #1 and 4. Added exclusion #2 and 23 (other criteria renumbered 
accordingly); updated exclusion #1, 4, 5, 8, 10, 12, 13, 14, 15, and 25. 
Amended Wording: 
Inclusion #1: Male or female, between 18 and 85 79 years of age, inclusive. The lower age 
limit may be higher if it is legally required in the participating country  
Inclusion #4: Uncontrolled hypertension (Grade 1 to 2 systolic hypertension – 
ESC/ESH), defined as: 
o Trough Resting trough-cuff seated SBP  140 and  179 mmHg based on the mean 
of at least 2 current consecutive clinic blood pressure readings at Screening and at the 
end of the placebo run-in period (Visit 3); AND 
o Currently on the maximally 2 or more antihypertensive medications, which have 
been titrated upward as tolerated dose of 2 or more to recommended hypertension 
medications with complementary mechanisms target doses (such as diuretics [except 
for potassium-sparing diuretics], renin-angiotensin system blockers, and/or calcium 
channel blockers, One of the antihypertensive medications must be high ceiling 
diuretic (loop or thiazide-like), unless there is a documented intolerance or 
contraindication to diuretic therapy. one of which the antihypertensive medications 
must be a diuretic at an appropriate dose of high ceiling [eg, loop or thiazide-like] 
unless not tolerated as the baseline medication), with no). The doses of the 
antihypertensive medications should be stable without any dose adjustment during 
the 30 days prior to randomization; OR 
o History of Patients with uncontrolled hypertension and moderate-to-severe CKD 
with documented history of intolerance or lack of efficacy while on to multiple 
hypertension antihypertensive medications on fewer than 2 antihypertensive 
medications; 
Exclusion #1: Resting trough Trough-cuff seated SBP > 180 or < 140 mmHg, based on 
the mean of at least 2 current consecutive clinic blood pressure readings at Screening and 
the end of the placebo run-in period (Visit 3); 
Exclusion #2: Serum potassium > 4.8 mmol/L; 
Exclusion #4: Currently on an MRA (eg, spironolactone or eplerenone) other than KBP-
5074, or received any MRAs during the last 3 months prior to Screening, or currently on 
any potassium supplements; 
Exclusion #5: Currently on Chronic or intermittent use of a potassium lowering agent, 
including insulin plus glucose infusion or have routinely or chronically used 
potassium-binding resins binder for the treatment of hyperkalemia within from 3 months 
prior to Screening until the end of study assessments, including but not limited to calcium 
polystyrene sulfonates (eg, sorbisterit, calcium resonium), sodium polystyrene sulfonates 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
6
(eg, kayexalate, anti-kalium sodium), and patiromer (eg, veltassa) (unless clinically 
indicated on an emergent basis to treat hyperkalemia until serum potassium values are 
within the normal range [see Section 8.12]);Veltassa™) and sodium zirconium 
cyclosilicate (eg, Lokelma™);  
Exclusion #8: Clinically History of clinically significant hyperkalemia while on an 
angiotensin converting enzyme inhibitor, angiotensin receptor blocker, direct renin 
inhibitor, and/or MRA, requiring down-titration or discontinuation of above 
medication, or hospitalization for hyperkalemia within during the last 3 months prior to 
Screening, or hyperkalemia > 5.6 mmol/L during the 2 weeks prior to Screening; 
Exclusion #10: Currently receiving hemodialysis/peritoneal dialysis or plan to start 
hemodialysisHD, or peritoneal dialysis within 3 months prior to Screening, or history and 
those patients with an episode of acute kidney injury that require dialysis within 3 months 
of Screening; 
Exclusion #11: History of a kidney renal transplant, or on a list for a kidney impending 
renal transplant; 
Exclusion #12: Acute decompensated heart failure including exacerbation of chronic heart 
failure manifested by signs and symptoms that may require hospitalization and/or 
intravenous diuretic therapy (New York Heart Association Class III to IV) within 3 months 
prior to Screening, or presence of hemodynamically significant valve diseases and/or other 
hemodynamically significant obstructive lesions of left ventricular outflow tract; 
Exclusion #13: Major cardiac, cerebral, and/or carotid artery diseases, including but not 
limited to acute coronary syndrome, myocardial infarction, stroke, and/or transient 
ischemic attack; major cardiovascular surgery or percutaneous procedures including 
cardiac ablation, coronary revascularization, and carotid angioplasty within 6 months 
prior to Screening; OR 
Any of those Cardiovascular conditions that are likely to require surgical or percutaneous 
intervention within 36 months from Screening; 
Exclusion #14: History of clinically significant arrhythmia, including but not limited to any 
of the following: 
o Symptomatic bradycardia and/or symptomatic ventricular arrhythmia within 3 
months prior to Screening; or 
o Second- or third-degree heart block; or 
o New onset or untreated atrial fibrillation; Note: Patients with stable (6 
months) asymptomatic rate controlled atrial fibrillation on appropriate 
therapy, which may include anticoagulation, are permitted. 
Exclusion #15: QT interval corrected using Fridericia’s formula (QTcF) > 450 ms for 
males or > 470 ms for females at Screening or Day 1; QTcF should be the average of the 
required triplicate set of ECGs at each timepoint;  

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
7
Exclusion #23: History of malignancy in the past 5 years, with the exception of basal 
or resected cutaneous squamous cell carcinoma of the skin or carcinoma in situ, 
prostate cancer in situ with a normal prostate-specific antigen post treatment, 
cervical carcinoma in situ, gastric cancer in situ, colon cancer in situ adequately 
treated with no progression over the past 2 years; 
Exclusion #25: Positive screen for drugs of abuse (except for patients with a A positive 
drug screen test (excluding a positive result secondary to a prescribed medication from a 
physician, or tetrahydrocannabinol) at Screening or the end of the run-in period (Visit 3);   
7. Section 5.1 sentence added to reflect current practice regarding diuretic therapy. 
The duration of the double-blind treatment period will be 84 days. Patients will remain on 
their stable antihypertensive medication (ie, no change in antihypertensive medication) 
throughout the entire study (including both the run-in and treatment periods). The dose of 
diuretic may be adjusted based on developing or resolved edema, weight gain or loss, 
or pulmonary congestion.  
8. Section 5.6 updated to reflect current practice regarding diuretic therapy. 
Section 5.6.1 Excluded Medications and/or Procedures 
Use of the following medications is not permitted during the study: 
• MRAs other than KBP-5074; 
• Potassium lowering agents, including insulin plus glucose infusion or routinely or 
chronically binders used for treatment of hyperkalemia within from 3 months prior 
to Screening until the end of study assessments, including but not limited to calcium 
polystyrene sulfonates (eg, sorbisterit, calcium resonium), sodium polystyrene (eg, 
kayexalate, anti-kalium sodium), patiromer (eg, veltassa) (unless clinically 
indicated on an emergent basis to treat hyperkalemia until serum potassium values 
are within the normal range [see Section 8.12]);Veltassa™) and sodium zirconium 
cyclosilicate (eg, Lokelma™); 
• Potassium-sparing diuretics (eg, amiloride, triamterene) within 3 months prior to 
Screening until the end of study assessments; 
• Potassium supplements (unless clinically indicated on an emergent basis to treat 
hypokalemia until serum potassium values are within the normal range [see 
Section 8.12]); 
• Hemodialysis/peritoneal dialysis; 
• Any nutrients known to modulate CYP3A activity (based on the KBP-5074 
metabolic pathway) or any strong or moderate inhibitors or inducers of CYP3A4, 
starting from 14 days prior to the first dose of study drug at Day 1 until the end of 
study assessments, including, but not limited to the following: inhibitors, such as 
ketoconazole, miconazole, itraconazole, fluconazole, atazanavir, erythromycin, 
clarithromycin, ranitidine, and cimetidine, and inducers, such as rifampicin, 
rifabutin, 
systemic 
glucocorticoids 
(inhaled 
and 
topical 
permitted), 
carbamazepine, phenytoin, phenobarbital, and St. John’s wort; and 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
8
• Any other medications (prescription drugs, herbal products, vitamins, minerals, and 
over-the-counter medications) that potentially increase serum potassium levels 
and/or cause toxicity to the kidney, including but not limited to renin inhibitors 
chronic or daily use of nonsteroidal anti-inflammatory drugs. These 
medications should be taken only if the Investigator considers these medically 
necessary. It is recommended that serum potassium levels and eGFR values should 
be closely monitored when patients take these medications. 
Section 5.6.2 Restricted Medications and/or Procedures 
Patients will be advised to maintain their normal diet and avoid unhealthy levels of 
not take alcohol use or potassium-rich foods/drinks during the study period. See Section 
8.12 for more details on monitoring of potassium and management of elevated serum 
potassium. 
Section 5.6.3 Documentation of Prior and Concomitant Medication Use 
All medications in addition to the study drug (including vitamin preparations) that are 
taken by the patient during the study must be documented as concomitant medications 
and reported on the corresponding eCRF. The use of sodium bicarbonate or dosage 
adjustment for treatment of acidosis in CKD is permitted. 
Patients must currently be on the maximally tolerated dose of 2 or more 
antihypertensive medications, which have been titrated upward as tolerated to 
recommended hypertension target doses hypertension medications with 
complementary mechanisms (such as diuretics [except for potassium sparing 
diuretics], renin angiotensin system blockers, and/or calcium channel blockers.1 of 
which One of the antihypertensive medications must be high ceiling diuretic (loop 
or thiazide-like), unless there is a documented intolerance or contraindication to 
diuretic therapy. One of the antihypertensive medications must be a diuretic at an 
appropriate dose of high ceiling (eg, loop or thiazide-like) unless not tolerated as the 
baseline medication) with no medications. The doses of the antihypertensive 
medications should be stable without dose adjustment during the 30 days prior to 
randomization. The dose of and/or types of the antihypertensive medications they are 
receiving during the screening period and throughout the duration of the study (unless 
they develop symptomatic hypotension) diuretic may be adjusted based on 
developing or resolved edema, weight gain or loss, or pulmonary congestion.  

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
9
Section 5.6.4 Management of Other Co-Morbidities 
For pPatients who have other additional co-morbidities (eg, diabetes, hyperlipidemia, 
and cardiovascular disease diseases) appropriate treatments, such as anti-
hyperlipidemia ), should be managed and treated with glucose lowering, lipid 
lowering, and anti-platelet and anti-hyperglycemia therapies are as recommended by 
according to local clinical practice guidelines. It is highly recommended that any 
medical treatments for these co-morbidities will not be changed during the study period 
(from Screening to the End of Study Visit [Day 112]/Early Termination Visit). 
9. Section 6 Study Procedures subsections updated to reflect use of a validated, oscillometric 
upper arm blood pressure monitor used to obtain blood pressure measurements. 
Original Wording: 
o Note: Patients must have uncontrolled hypertension, defined as resting trough-cuff 
seated SBP  140 mmHg, based on the mean of at least 2 current consecutive blood 
pressure readings in the clinic; 
o Note: Blood pressure measurement: Blood pressures are obtained according to the 
American Heart Association (AHA) recommendations10 for accurate blood pressure 
measurement. Patients should avoid smoking, caffeine, or exercise within 30 minutes 
before measurement; empty his or her bladder; then sit quietly in a comfortable chair 
with back support for at least 10 minutes before a measurement; and remain still during 
the measurement. The patient’s limb should be supported to measure blood pressure 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not 
take the measurement over clothes. Blood pressure measurements should be performed 
in the same arm throughout the study;  
o Note: Triplicate blood pressure measurements should be taken approximately 
2 minutes apart with the patient in the seated position and having rested for at least 10 
minutes prior to assessment. Trough-cuff SBP and DBP values will be assessed based 
on the pre-defined blood pressure measurement guideline throughout the study; 
o Note: Blood pressure and pulse rate will be measured at the same time;  
o Note: Measurement will be taken with OMRON HEM-705-CP automated blood 
pressure machine; 
Amended Wording (all subsections replaced): 
• Note: Patients must have uncontrolled hypertension, defined as resting trough-cuff seated 
SBP  140 and  179 mmHg, based on the mean of at least 2 current consecutive blood 
pressure readings in the clinic; 
• Blood pressures are to be obtained according to the AHA recommendations for accurate 
blood pressure measurement. Patients should avoid smoking, caffeine, or exercise within 
30 minutes before measurement; empty his or her bladder; then sit quietly in a comfortable 
chair with back support for at least 10 minutes before measurement and remain still during 
the measurement. The patient’s limb should be supported to measure blood pressure to 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not take 
the measurement over clothes. Blood pressure measurements should be performed in the 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
10 
same arm throughout the study. Triplicate blood pressure measurements should be taken 
approximately 2 minutes apart with OMRON HEM-705-CP automated blood pressure 
machine a validated, oscillometric upper arm blood pressure monitor. Trough cuff 
SBP and DBP values will be assessed based on the pre-defined blood pressure 
measurement guideline throughout the study. Pulse will be obtained simultaneously with 
blood pressure measurements. 
Clarified that laboratory samples do NOT need to be obtained in a fasting state. 
Added where appropriate: Note: Serum potassium should be  4.8 mmol/L (local lab) to 
advance or continue to the placebo run-in Period. 
Section 6.4 changed from Double-Blind Treatment Period to Randomization and 
Treatment 
Section 6.4.2: The following procedures will be performed at Visit 4: 
• Assess eligibility: Prior to randomization, all patients are to have a serum 
potassium  4.8 mmol/L at both Screening and the end of the placebo run-in 
period; and a mean (Visit 1 and Visit 3) eGFR  15 and  44 mL/min/1.73 m2. 
10. Section 8.2 Adverse Events of Special Interest 
• Hypertensive emergency defined;  
o Defined as confirmed (based on the mean of at least 2 current consecutive 
protocol-required blood pressure readings, or otherwise obtained blood pressure 
readings) with severe elevation in SBP > 180 mmHg and/or DBP >120 mmHg with 
associated new or progressive target organ damage, neurologic, and/or cardiac 
symptoms. Blood pressures of > 200 mmHg in asymptomatic patients, a confirmed 
elevation in SBP 200 mmHg, regardless of DBP. If SBP >200 mmHg or DBP >120 
mmHg and the patient is symptomatic, the blood pressure measurement should be 
repeated approximately every 10 minutes over a 30 minute period with the patient 
resting in a quiet, comfortable environment to confirm the recorded in the eCRF, and 
Investigators must differentiate between hypertensive urgency (marked elevated 
blood pressure) and emergency. See Section 8.14 and Appendix C for definition 
and management of hypertensive emergencies and urgencies; and  
o Symptomatic hypotension, or if the defined as symptoms associated with an SBP 
< 90 mmHg after the first dose of study drug at Day 1. 
11. Contact information updated in Section 8.4 for reporting SAEs. 
• Site staff will complete the paper SAE report form and e-mail it within 24 h to the following 
address: drugsafety@worldwide.com 
• In cases where the email system is unavailable, site staff will send the SAE by fax to: 
+1-866-387-5539 (US) and +44 208 043 4813 (ROW). 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
11 
12. Section 8.7 Clinical Laboratory Evaluations deleted need for samples to be obtained after at 
least a 10 hour fast. 
13. Section 8.12 Safety Surveillance and Management of Serum Potassium Levels updated to 
reflect more stringent surveillance of potassium levels 
Serum potassium levels of study patients will be monitored systematically throughout the 
study. In addition to the clinical laboratory tests pre-defined in the Schedule of Procedures 
(Appendix A), unscheduled assessments of serum potassium levels are recommended under 
certain situations (eg, vomiting and/or diarrhea for  1 day) that may impact patients’ serum 
electrolyte levels or fluid balance. 
In patients with serum potassium above the normal laboratory reference range (serum 
potassium levels  5.0 mmol/L), it is advised that the Investigator should reinforce enforce 
dietary restriction for management of elevated potassium and consider local guideline 
recommendations. For diabetes patients, in addition to dietary restrictions and clinical 
management of hyperkalemia, the investigator should also enforce adequate glycemic control. 
Table 1 below summarizes the laboratory testing for assessment of serum potassium levels 
 5.0 mmol/L and guidelines for management of study drug, which includes continuation 
thereof, holding of study drug, and/or discontinuation of study drug. If serum potassium levels 
are < 5.0 mmol/L, no action is indicated. A serum potassium level of  5.6 mmol/L requires a 
hold of study drug and appropriate retesting and intervention as described in Table 1. A 
potassium level of  6.0 mmol/L necessitates immediate and permanent discontinuation of 
study drug.  
Because of potential issues anticipated from routine sample handling and extended 
transportation time to the central laboratory, falsely elevated serum potassium values 
pseudohyperkalemia secondary to hemolysis may occur in centralcentrally analyzed 
laboratory analyzed samples may be expected. For this reason, during treatment with study 
drug, all serum potassium assessments, including retests, will be performed at both local and 
central laboratories. 
In general, if the initial local and/or central laboratory test shows that a patient’s serum 
potassium level is  5.3 mmol/L, a repeat local test is required to confirm elevation of serum 
potassium levels and dictate actions to be taken as outlined in Table 1. In the absence of 
hemolysis, the more conservative value from the central or local laboratories should be used. 
Results from the local laboratory will usually be used for the immediate decision process and 
for safety purposes. All samples should be screened for hemolysis to eliminate the 
possibility of pseudohyperkalemia. Results from the central laboratory will be used for 
data analysis. If a major discrepancy exists between the local and central laboratory 
values, defined as a ± 0.3 mmol/L difference between values or if hemolysis is noted in the 
specimens, repeat blood samples should be obtained to confirm eligibility or continuation 
in the study. Again, decisions to enroll or randomize a patient should generally be based 
on the local serum potassium. However, if the central laboratory serum potassium is  4.8 
mmol/L and the local potassium test is > 4.8 mmol/L, the more conservative value may 
be used if the difference between the 2 samples is  0.3 mmol/L.11 
Recheck of serum potassium values must be done as quickly as possible and at the latest Serum 
potassium recheck is recommended within 24, 48, or 72 hours, of the depending on the 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
12 
level of hyperkalemia, following Investigator being aware of results that need 
retest/confirmation as outline in notification of a serum potassium  5.3 mmol/L (see 
Table 1). The Investigator can perform a retest at any time if it is considered necessary 
additional serum potassium retests when clinically indicated for routine medical issues 
conditions or procedures that might arise occur during the study to confirm the potassium 
concentration of either the local or central laboratory sample. The repeated test must be 
conducted using. Blood samples should be obtained atraumatically, without fist clenching 
or prolonged use of a non tourniquet. Non-hemolyzedsample and blood samples sent for 
rechecks or retests will be analyzed in both local and central laboratories. In some 
circumstances, as outlined below in Table 1, a second retest may be indicated and should be 
performed within 1 week to allow the patient to adjust to the withdrawal of study drug (if 
indicated) and application of standard of care. All episodes of hyperkalemia, serum 
potassium of > 5.0 mmol/L should be reported as an adverse event of special interest. 
The monitoring of serum potassium and the decision on whether or not to discontinue study 
drug, as well as other interventions, are outlined in Table 1. 
Original Table 1  
 
Value of the First Serum Potassium Assessment 
5.0 to 5.2 mmol/L 
5.3 to 5.5 mmol/L 
5.6 to 5.9 mmol/L 
6.0 mmol/L 
Laboratory test 
at both local and 
central 
laboratories [1] 
 
Repeat serum 
potassium test within 
24 hours. 
Repeat serum 
potassium test within 
24 hours. 
Repeat serum 
potassium test within 
24 hours. 
Intervention 
Enforce dietary 
restriction for 
management of 
elevated potassium. 
For diabetic 
patients, also 
enforce adequate 
glycemic control. 
Continue study drug 
pending retest results. 
 
Withhold study drug 
pending retest results. 
Permanently 
discontinue study drug 
immediately. 
 
 
Manage hyperkalemia 
per standard of care 
(but no potassium-
binders). 
 
Manage hyperkalemia 
per standard of care 
(but no potassium-
binders). 
Manage hyperkalemia 
per standard of care. 
 
If serum potassium 
<5.3 mmol/L on retest, 
no changes are 
indicated. 
 
If serum potassium 
<5.3 mmol/L on retest, 
resume study drug. 
Enforce dietary 
restriction for 
management of 
elevated potassium. For 
diabetes patients, also 
enforce adequate 
glycemic control. 
 
 
1. 
If serum 
potassium on 
retest is 5.3 
mmol/L to 
5.5 mmol/L, 
temporarily 
discontinue study 
drug, consider use 
of loop diuretics 
and do second 
retest within 1 
week. 
 
If serum potassium 
level on retest is >5.3 
mmol/L, consider use 
of loop diuretics and 
do second retest within 
1 week. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
13 
 
If serum potassium on 
second retest is 
>5.3 mmol/L, 
permanently 
discontinue study 
drug. 
 
If serum potassium on 
second retest is 
>5.5 mmol/L, 
permanently 
discontinue study 
drug. 
 
 
Enforce dietary 
restriction for 
management of 
elevated potassium. 
For diabetic patients, 
also enforce adequate 
glycemic control. 
Enforce dietary 
restriction for 
management of 
elevated potassium. 
For diabetes patients, 
also enforce adequate 
glycemic control. 
 
2. 
In the absence of hemolysis, the more conservative value from the central or local laboratories should be used. 
In general, if serum potassium levels are 5.3 mmol/L, repeat testing is necessary and the procedures summarized above 
should be followed. 
The Investigator should consider local guideline recommendations for management of serum potassium levels above the 
normal laboratory reference range. In all instances, dietary restriction for management of elevated potassium should be 
enforced. In addition, in diabetic patients, adequate glycemic control should be enforced. Consider use of loop diuretics as 
appropriate to manage hyperkalemia. If treatment with potassium-binding resins is required, the patient should be permanently 
discontinued from study drug. 
Elevated serum potassium levels should be analyzed locally and centrally to rule out hemolysis. If the locally analyzed blood 
sample is missing, or the result is inconclusive, another blood sample should be taken as soon as possible but no later than 
24 hours to confirm the value. 
The study Sponsor or delegate will be notified by site personnel within 24 hours of the site being aware of results for any local 
laboratory potassium value (5.3 mmol/L). Retest/confirmatory testing results will be forwarded to the Sponsor or delegate 
within 24 hours of the site being aware of results. 
 
Replacement Table 1 to be presented in landscape format in the protocol text.  
 
Alert Local and Central Laboratory Serum Potassium (K+) Values 
> 5.0 to 
5.2 mmol/L 
5.3 to 5.5 mmol/L 
5.6 to 5.9 mmol/L 
 6.0 mmol/L 
Following 
notification of a 
serum K+ alert 
value1 
 
 
Contact patient and 
schedule repeat serum K+ 
within 24-72 hours after 
laboratory notification. 
Contact patient and 
schedule repeat serum K+ 
within 24-48 hours after 
laboratory notification. 
Contact patient and 
schedule repeat serum K+ 
within 24 hours after 
laboratory notification. 
Management  
Continue 
study drug. 
Continue study drug 
pending retest results. 
 
Hold study drug pending 
retest results. 
Permanently discontinue 
study drug. 
Treatment 
Reinforce low 
K+ diet.  
Reinforce low- K+ diet; 
manage HK per local SOC 
(no K+ binders). 
Reinforce low- K+ diet; 
manage HK per local SOC 
(no K+ binders). 
Reinforce low- K+ diet; 
manage HK per local SOC 
(may use K+ binders)..  
If first serum 
K+ retest is 
< 5.3 mmol/L 
Continue study drug.  
 
Resume study drug.  
 
 
 
 
 
Note: Following 
discontinuance of study 
drug continue study visits 
and safety monitoring.  
 
 
 
 
 
Management 
following first 
serum K+ retest 
If retest serum K+ is  5.3 
to 5.5 mmol/L: 
1. 
Hold study drug,  
2. 
Consider higher dose 
of diuretic,  
3. 
Schedule second 
serum K+ retest within 
1 week. 
 
If retest serum K+ 
> 5.5 mmol/L, 
If retest serum K+ is  5.3 to 
5.5 mmol/L: 
1. 
Continue to hold study 
drug,  
2. 
Consider higher dose 
of diuretic,  
3. 
Schedule second serum 
K+ retest within 
1 week.  
If retest serum K+ 
> 5.5 mmol/L, 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
14 
 
Alert Local and Central Laboratory Serum Potassium (K+) Values 
> 5.0 to 
5.2 mmol/L 
5.3 to 5.5 mmol/L 
5.6 to 5.9 mmol/L 
 6.0 mmol/L 
permanently discontinue 
study drug. 
permanently discontinue 
study drug.  
 
 
 
 
Report as AE as Special 
Interest 
Management 
following 
second serum 
K+ retest 
If serum K+ on retest is 
< 5.3 mmol/L, continue 
study drug. 
 
If serum K+ on retest is 
 5.3 mmol/L, 
permanently discontinue 
study drug. 
If serum K+ is 
< 5.3 mmol/L, resume study 
drug.  
 
If serum K+ on retest is 
 5.3 mmol/L, 
permanently discontinue 
study drug.  
Adverse Event 
Reporting 
Report as AE of Special 
Interest 
Report as AE of Special 
Interest 
1 
In the absence of hemolysis, the more conservative value from the central or local laboratories should be used to guide 
management and treatment 
 
Study sites should make repeated attempts to contact patients with high K+ or HK to ensure compliance with K+ safety 
monitoring and required retests. 
 
If the serum K+ levels are  5.3 mmol/L, repeat local and central serum K+ testing is required in compliance with the 
above management strategies and procedures  
 
The Investigator should consider local guideline and SOC for management of serum potassium levels above the normal 
laboratory reference range. In all instances, dietary restriction for management of elevated potassium should be 
reinforced. Consider use of higher dose of loop or thiazide-like diuretics to manage HK. If chronic or intermittent 
treatment with potassium-binders is required, the patient should be permanently discontinued from study drug.  
 
If the locally analyzed blood sample is missing, or the result is inconclusive, another blood sample should be taken as 
soon as possible but no later than 24 to up to 72 hours to confirm the value. 
 
The Sponsor or delegate will be notified by site personnel within 24 hours of the site being aware of results for any local 
laboratory potassium value ( 5.3 mmol/L). Retest/confirmatory testing results will be forwarded to the Sponsor or 
delegate within 24 hours of the site being aware of results. 
Abbreviations: K+: potassium, HK: hyperkalemia, SOC: Standard of care. 
Regardless of whether a patient will discontinue study drug due to elevated serum potassium 
levels, he/she should be closely monitored and treated, as appropriate, per the Investigator’s 
assessment.  
14. Section 8.14 Monitoring and Management of Blood Pressure updated to reflect current 
practices.  
Blood pressure will be closely monitored throughout this study. At Screening, patients must 
have uncontrolled hypertension, defined as resting trough-cuff seated SBP  140 and 
 179 mmHg based on the mean of at least 2 current consecutive blood pressure readings at 
Screening and the end of the run-in period in the clinic. Blood pressures are obtained 
according to the AHA recommendations for accurate blood pressure measurement. 
Patients should avoid smoking, caffeine, or exercise within 30 minutes before 
measurement; empty his or her bladder; then sit quietly in a comfortable chair with back 
support for at least 10 minutes before a measurement; and remain still during the 
measurement. The patient’s limb should be supported to measure blood pressure and 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not 
take the measurement over clothes. Blood pressure measurements should be performed 
in the same arm throughout the study. Measurement will be taken with a validated, 
oscillometric upper arm blood pressure monitor. 
In all cases, dose and frequency of concurrent antihypertensive medications are expected to be 
maintained without change for 30 days prior to randomization. In general, patients should not 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
15 
add or adjust dose and/or types of the antihypertensive medications they are receiving during 
the screening period and throughout the duration of the study (unless they develop 
symptomatic hypotension). The dose of diuretic may be adjusted based on developing or 
resolved edema, weight gain or loss, or pulmonary congestion. Antihypertensive therapy 
may be modified if necessary during the safety assessment, following withdrawal of the 
study drug to maintain blood pressure control.  
The following guidelines are based on the 2017 Guideline for the Prevention, Detection, 
Evaluation, and Management of High Blood Pressure in Adults.1A hypertensive emergency is 
defined as a confirmed (based on the mean of at least 2 current consecutive protocol-required 
blood pressure readings, or otherwise obtained blood pressure reading) severe elevation in SBP 
>180 mmHg and/or DBP >120 mmHg with neurologic and/or cardiac symptoms, or, in 
asymptomatic patients, a confirmed elevation in SBP >200 mmHg, regardless of DBP. A 
confirmed (based on the mean of at least 2 current consecutive protocol-required blood 
pressure readings, or otherwise obtained blood pressure reading) asymptomatic DBP of >120 
mmHg should also be managed as a hypertensive emergency, regardless of the SBP. If  SBP 
>200 mmHg or DBP >120 mmHg and the patient is asymptomatic, the blood pressure 
measurement should be repeated approximately every 10 minutes over a 30-minute period, 
with the patient resting in a quiet, comfortable environment to confirm the elevated blood 
pressure. 
Hypertensive emergencies demand immediate medical intervention to reduce blood pressure 
per local practice guidelines and the medical judgment of the Investigator. Reduction of blood 
pressure (not necessarily to normal ranges) are required to prevent or limit further target organ 
damage, which can include hypertensive encephalopathy, intracranial hemorrhage, acute 
ischemic stroke, acute myocardial infarction, acute left ventricular failure with pulmonary 
edema, unstable angina pectoris, dissecting aortic aneurysm, acute renal failure, and eclampsia. 
Employment of pharmacological classes that are available for the treatment of hypertensive 
emergencies should be used per local guidelines. In general, autoregulation of tissue perfusion 
is disturbed in hypertensive emergencies; thus, continuous infusion of short-acting titratable 
antihypertensive agents is often preferred; use of oral therapy is discouraged for hypertensive 
emergencies.  
Diagnoses of hypertensive emergency require discontinuance of the study drug, and 
immediate treatment per local treatment guidelines. The occurrence of hypertensive 
urgency or a transient severe elevation in blood pressure may or may not require removal 
of a patient from the study drug but should be recorded as an adverse event and reviewed 
with the study Medical Monitor. AHA/American College of Cardiology definitions, 
clinical definitions, and treatment algorithms for hypertensive emergency, hypertensive 
urgency, or marked elevations in blood pressure appear in Appendix C. 
It should be noted that hypertensive emergencies in patients presenting with acute intracranial 
hemorrhage and acute ischemic stroke require particularly close management; local guidelines 
for such patients should be followed. 
If a patient developsSymptomatic hypotension or (defined as a confirmed trough-seated 
SBP < 90 mmHg based on the mean of at least 2 current consecutive protocol-required blood 
pressure readings, or otherwise obtained blood pressure reading after the first dose of study 
drug at Day 1, should be reported as an adverse event of special interest. Investigators 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
16 
should evaluate and correct any potential reasons that may contribute to hypotension, such as 
dehydration, decreased blood volume, potential overdose of antihypertensive medication 
(including study drugs), etc. If symptomatic hypotension or a confirmed trough-seated 
SBP < 90 mmHg occurs, Investigators the patient’s hypertension still has hypotension, 
Investigators may consider down-titration of antihypertensive medications (other than study 
drug) first. If symptomatic hypotension or a confirmed trough-seated SBP < 90 mmHg persists 
following down-titration, patient’s hypotension remains study drug should be permanently 
discontinued. 
15. Section 9.2.6 Independent Data Monitoring Committee updated to provide meeting schedule: 
Meeting Schedule 
After the organizational meeting, the IDMC will meet at least 4 times during the conduct of 
the study at the following treatment milestones: 
• Approximately 10% of patients completed are randomized in the study,  
• Approximately 25% of patients completed the 12-week treatment period,  
• Approximately 50% of patients completed the 12-week treatment period, and 
• Approximately 75% of patients completed the 12-week treatment period. 
16. Section 12 Study Administrative Information updated to reflect the changes in organizations 
involved in the conduct of the study.  
17. Section 13 References updated to add references 9, 10, and 12.  
18. Appendix A updated to delete Contact IRT at Day 7; to add footnote #16 (subsequent 
footnote numbers updated) ‘All patients must have a serum potassium  4.8 mmol/L at both 
Screening and the end of the placebo run-in period (Visit 3)’; updated wording of footnote 
#10 ‘At Screening and the end of the placebo run-in period (Visit 3), patients must have 
uncontrolled hypertension, defined as resting trough-cuff seated SBP  140 mmHg and 
 179 mmHg based on the mean of at least 2 current consecutive blood pressure readings in 
the clinic.’; deleted need for obtaining blood samples in fasting state in footnote #14; added 
Assessment for Randomization; abbreviations for DBP and SBP added. 
19. Appendix C added.  
20. Minor typographical errors and wording preferences updated throughout the protocol.  

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
17 
SYNOPSIS 
TITLE:  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to 
Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients with 
Moderate-to-Severe Chronic Kidney Disease and Uncontrolled Hypertension – (BLOCK/CKD) 
PROTOCOL NUMBER:  KBP5074-2-001 
INVESTIGATIONAL PRODUCT:  KBP-5074 
PHASE:  2 
INDICATION:  Uncontrolled hypertension (Grade 1 to 2 systolic hypertension – European 
Society of Cardiology [ESC]/European Society of Hypertension [ESH]) in patients with 
moderate-to-severe chronic kidney disease (CKD) 
OBJECTIVES: 
The primary objective of this study is to evaluate the efficacy of KBP-5074 in patients with 
moderate-to-severe CKD on uncontrolled hypertension (eg, Grade 1 to 2 systolic hypertension – 
ESC/ESH) as determined by change in trough-cuff seated systolic blood pressure (SBP) from 
baseline to Day 84. 
The secondary objectives of this study are the following: 
• To evaluate the change in trough-cuff seated diastolic blood pressure (DBP) from baseline to 
Day 84;  
• To evaluate the change in 24-hour mean, daytime mean, nighttime mean, morning mean, last 
6 hours of the dosing interval mean, SBP, DBP, mean arterial pressure (MAP), and heart 
rate (HR) from baseline to Day 84 in a subset of up to 40 patients per treatment group as 
measured by 24-hour ambulatory blood pressure monitoring (ABPM); 
• To evaluate the change and percent change in urine albumin-to-creatinine ratio (UACR) from 
baseline to Day 84 (for patients with albuminuria [defined as UACR > 300 mg/g] or 
microalbuminuria [defined as UACR in the range of 30 mg/g to 300 mg/g]); 
• To evaluate the change in serum aldosterone and plasma renin levels from baseline to Day 84; 
• To evaluate the incidence of hyperkalemia (defined as serum potassium  5.6 mmol/L), 
incidence of severe hyperkalemia (defined as serum potassium  6.0 mmol/L), and incidence 
of patients with serum potassium > 5.0 mmol/L; 
• To evaluate the change in serum potassium levels from baseline to Day 84; 
• To evaluate the changes in estimated glomerular filtration rate (eGFR) and creatinine levels 
> 30% throughout the study period; and 
• To evaluate population pharmacokinetics (PPK) of KBP-5074. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
18 
POPULATION: 
The population for this study will be male and female patients 18 to 85 years of age, inclusive, 
with Stage 3B/4 CKD (defined as eGFR  15 and  44 mL/min/1.73 m2, based on the isotope 
dilution mass spectrometry traceable Modification of Diet in Renal Disease equation version 4, 
according to central laboratory results at Screening). Patients are to have uncontrolled 
hypertension (Grade 1 to 2 systolic hypertension – ESC/ESH) defined as: 
• Resting trough-cuff seated SBP  140 and  179 mmHg based on the mean of at least 2 current 
consecutive clinic blood pressure readings at Screening and at the end of the placebo run-in 
period (Visit 3) and at randomization (Visit 4), AND 
• Currently on 2 or more antihypertensive medications, which have been titrated upward as 
tolerated to recommended hypertension target doses (such as diuretics [except for 
potassium-sparing diuretics], renin-angiotensin system blockers, and/or calcium channel 
blockers.  One of the antihypertensive medications must be high ceiling diuretic (loop or 
thiazide-like), unless there is a documented intolerance or contraindication to diuretic therapy. 
The doses of the antihypertensive medications should be stable without any dose adjustment 
during the 30 days prior to randomization; OR 
• Patients with uncontrolled hypertension and moderate-to-severe CKD with documented 
history of intolerance to multiple antihypertensive medications on fewer than 
2 antihypertensive medications.  
All patients are to have a serum potassium  4.8 mmol/L at both Screening and the end of the 
placebo run-in period; and a mean (Visit 1 and Visit 3) eGFR  15 and  44 mL/min/1.73 m2. 
STUDY DESIGN AND DURATION: 
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center study to assess the 
efficacy, safety, and pharmacokinetics (PK) of KBP-5074 in patients with moderate-to-severe 
CKD and uncontrolled hypertension (Grade 1 to 2 systolic hypertension – ESC/ESH).  
The study will enroll approximately 240 patients, randomized in a 1:1:1 ratio to 1 of 3 treatment 
groups (80 patients in each group): KBP-5074 0.25 mg once daily (QD), KBP-5074 0.5 mg QD, 
or placebo QD. Randomization will be stratified to balance enrollment for key variables that may 
influence safety and/or efficacy evaluations, including eGFR ( 30 versus < 30 mL/min/1.73 m2) 
and SBP ( 160 versus < 160 mmHg). Approximately 30% of patients enrolled in the study should 
have eGFR in the range of 15 to 29 mL/min/1.73 m2. The study will be approximately 5 months 
in duration with 84 days of double-blind treatment.  
The study will consist of up to a 4-week screening period, 2-week open-label (placebo) run-in 
period, 84-day double-blind treatment period, and a 4-week post-treatment safety follow-up 
period. 
Plasma samples for PK analysis will be collected from all patients. A total of 4 PK samples will 
be collected from each patient, including at Day 1 (prior to discharge), Day 14 pre-dose, Day 28 
pre-dose, and the End of Study Visit (Day 112)/Early Termination Visit. The pre-dose samples 
assume that patients will be dosed in the unit on the days above. If patients are not dosed in the 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
19 
unit on those days, a PK sample will be collected during each of these visits and the date and time 
of the last dose will be recorded. 
Safety will be assessed systematically, and an independent data monitoring committee will 
perform cumulative reviews of safety data at regular intervals during the study. 
Serum potassium levels, serum creatinine, and blood pressure will be monitored throughout the 
study and clinically significant changes will be reported as adverse events of special interest. 
At Screening and the end of the placebo run-in period (Visit 3), patients must have uncontrolled 
hypertension (Grade 1 to 2 systolic hypertension – ESC/ESH), defined as resting trough-cuff 
seated SBP  140 and  179 mmHg, based on the mean of at least 2 current consecutive blood 
pressure readings in the clinic, a serum potassium  4.8 mmol/L at Screening and the end of the 
placebo run-in period (Visit 3), and a mean (Visit 1 and Visit 3) eGFR  15 and 
 44 mL/min/1.73 m2. 
In all cases, dose and frequency of concurrent antihypertensive medications are expected to be 
maintained without dose adjustment for 30 days prior to randomization in order to ensure that 
blood pressure is stable. In general, patients should not add or adjust dose and/or types of the 
antihypertensive medications they are receiving during the screening period and throughout the 
duration of the study (unless they develop symptomatic hypotension). The dose of diuretic may 
be adjusted based on developing or resolved edema, weight gain or loss, or pulmonary congestion. 
Patients will be advised to maintain their normal diet and avoid unhealthy levels of alcohol use or 
potassium-rich foods/drinks during the study period. No potassium supplements are permitted, 
unless clinically indicated to treat hypokalemia on an emergent basis until serum potassium values 
are within the normal range. The use of potassium-sparing diuretics is not permitted within 
3 months prior to Screening until the end of study assessments. Intermitted or chronic use of 
potassium-binding drugs is not permitted for 3 months prior to Screening until the end of study 
assessments.  
After completion of the screening period and the qualifying Screening Visit, patients who meet 
all eligibility criteria (except those criteria scheduled to be assessed after the Screening Visit), will 
enter the 2-week, open-label (placebo) run-in period. At the end of the run-in period (Visit 3), 
patients will be reassessed for eligibility, including persistence of uncontrolled hypertension and 
compliance with open-label placebo received during the run-in period and current 
antihypertensive medication. If a patient’s compliance is < 80% or > 120%, the patient will not be 
eligible for the study, and no further visits will be performed.  
If a patient is found to be ineligible during Screening, a single rescreening is allowed if the 
Investigator believes that the patient’s medical condition has changed, and the patient may be 
eligible before the rescreening tests. Please note that a new patient number should be assigned to 
any rescreened patient, and all of the procedures defined in the protocol for the Screening Visit 
and during the run-in period must be repeated. 
Patients who meet all eligibility criteria at Visit 4/Day 1 will be randomized (stratified based on 
eGFR  30 versus < 30 mL/min/1.73 m2 and SBP  160 versus < 160 mmHg) into the study on 
Day 1. All randomized patients will receive double-blind treatment for 84 days. Patients will be 
followed for 4 weeks for safety assessments after the last dose of study drug. Antihypertensive 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
20 
therapy may be modified if necessary during the safety assessment, following withdrawal of the 
study drug, to maintain blood pressure control.  
A subset of up to 40 patients per treatment group who agree to participate in 24-hour ABPM and 
still meet eligibility criteria at the end of the run-in period (Visit 3) will undergo 24-hour ABPM 
on Day -1, Day 40, and Day 82. 
DOSAGE FORMS AND ROUTE OF ADMINISTRATION: 
At the Day 1 Visit, eligible patients will be randomized in a 1:1:1 ratio to the following treatment 
groups: 
• KBP-5074 0.25 mg QD orally,  
• KBP-5074 0.5 mg QD orally, or  
• Placebo QD orally. 
EFFICACY VARIABLES:  
The primary efficacy variable is the change in trough-cuff resting seated SBP from baseline to 
Day 84. 
The key secondary efficacy variables include the following: 
• Change in trough-cuff seated DBP from baseline to Day 84; 
• Change in 24-hour mean, daytime mean, nighttime mean, morning mean, last 6 hours of the 
dosing interval mean, SBP, DBP, MAP, and HR from baseline to Day 84 as measured by 
24-hour ABPM in a subset of up to 40 patients per treatment group; and 
• Change and percent change in UACR from baseline to Day 84 (for patients with albuminuria 
[defined as UACR > 300 mg/g] or microalbuminuria [defined as UACR in the range of 
30 mg/g to 300 mg/g]). 
PHARMACOKINETIC VARIABLES: 
Plasma samples for PK analyses will be collected from all patients at the visits indicated on the 
Schedule of Procedures (Appendix A). 
PHARMACODYNAMIC VARIABLES: 
The pharmacodynamic (PD) variable of this study is change in serum aldosterone and plasma 
renin levels from baseline to Day 84. 
Serum/plasma samples will be stored at central laboratory for determination of various additional 
biomarkers, including but not limited to galectin-3, N-terminal of the prohormone brain natriuretic 
peptide, interleukin-6, collagen biomarkers, and C-reactive protein. The panel of biomarkers and 
time points for analysis will be determined prior to the database lock. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
21 
SAFETY VARIABLES: 
Safety variables will include adverse events, vital signs (pulse rate, respiratory rate, and oral 
temperature), clinical laboratory findings, 12-lead electrocardiograms (ECGs), and physical 
examination findings. 
The following serum potassium/hyperkalemia-related parameters and renal function-related 
parameters will be collected and evaluated: 
• Incidence of hyperkalemia (defined as serum potassium  5.6 mmol/L), incidence of severe 
hyperkalemia (defined as serum potassium  6.0 mmol/L), and incidence of patients with 
serum potassium > 5.0 mmol/L; 
• Change in serum potassium levels from baseline to Day 84; and 
• Change in eGFR and creatinine levels > 30% throughout the study period. 
STATISTICAL ANALYSES: 
The Intent-to-Treat (ITT) Population will consist of all randomized patients who take at least 
1 dose of randomized study drug, have a baseline SBP measurement, and have at least 
1 post-randomization SBP measurement. The ITT Population is the primary analysis population. 
All efficacy analyses will be performed for the ITT Population. 
The Per-Protocol Population will include all ITT patients who have completed the 84-day 
double-blind treatment period without any major protocol deviations or violations. The 
Per-Protocol Population will be used to assess robustness of the primary analysis results. The 
major protocol deviations will be pre-specified prior to unblinding treatment codes for analyses. 
The Safety Population will include all randomized patients who receive at least 1 dose of 
randomized study drug. 
The population-pharmacokinetic (PPK) Population will include all randomized patients who 
receive at least 1 dose of randomized study drug and have at least 1 measurable concentration of 
total KBP-5074. 
The primary efficacy analysis is to evaluate the change in trough-cuff seated SBP from baseline 
to Day 84 for the KBP-5074 doses compared to placebo. The endpoint for each patient is defined 
as the Day 84 cuff seated SBP measurement. If the measurement at this visit is missing or the 
patient discontinues early, the last post-baseline measurement during the double-blind period will 
be used. 
The primary efficacy analysis will be carried out using a 2-way analysis of covariance (ANCOVA) 
model with treatment, baseline eGFR level ( 30 versus < 30 mL/min/1.73 m2), and background 
antihypertensive medication (2 or more) as factors, and the baseline SBP value as a covariate. The 
least-squares means, standard errors, and the 2-tailed 95% confidence intervals (CIs) for each 
treatment group and for the comparison will be estimated. The treatment difference between 
KBP-5074 doses and placebo will be estimated from the ANCOVA model. No multiple 
comparison adjustment will be used for this Phase 2 study. 
The primary efficacy analysis will be based on the ITT Population. Other imputation methods for 
the primary efficacy endpoint will be explored. The supportive analysis will be carried out for the 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
22 
primary efficacy variable based on the Per-Protocol Population to examine the impact due to 
premature dropouts and/or major protocol deviations or violations. 
For continuous secondary efficacy variables, the same ANCOVA model will be used as the 
primary efficacy analysis. For categorical data, logistic regression or chi-square test will be used. 
Treatment effects will be evaluated between KBP-5074 doses and placebo. 
Safety assessments will include monitoring of adverse events, vital signs (pulse rate, respiratory 
rate, and oral temperature), clinical laboratory findings, 12-lead ECGs, and physical examination 
findings. All safety analyses will be conducted on the total patient cohort based on the Safety 
Population. 
The assessment of safety will be based primarily on the frequency of patients with adverse events 
and clinical laboratory abnormalities. Other safety data will be summarized as appropriate. 
Adverse events will be coded using the Medical Dictionary for Regulatory Activities. Reports will 
be provided to the Medical Monitor for approval of the coded terms after the database is clean, 
prior to unblinding. The number and frequency of patients with treatment-emergent adverse 
events (TEAEs) (ie, those adverse events that newly occur or worsen in severity during the study) 
will be summarized by system organ class and preferred term. Serious adverse events (SAEs) and 
TEAEs related to study drug will be summarized in the same manner. A list of patients with SAEs 
and those who discontinue from the study due to an adverse event will be provided. 
Summary statistics by treatment group at baseline, at all post-randomization visits, and changes 
from baseline to the post-randomization visits for laboratory values will be provided. Occurrence 
of significant abnormalities in laboratory values from baseline will be summarized by treatment 
group. Vital signs, body weight, and physical examination findings will be summarized. 
The analysis of the PK/PD relationship will be explored. Population PK models will be built using 
a nonlinear mixed effects modeling technique with NONMEM software based on the 
PPK Population. Different PK models will be attempted to fit the PK concentration-time data. 
After the PPK modeling, a population PD approach will be used to explore the 
concentration-effect relationships. Different PD models will be attempted to fit the 
concentration-effect data. All PD exploration will be based on the ITT Population. 
SAMPLE SIZE DETERMINATION: 
For this Phase 2 study, the primary efficacy endpoint is the change in trough-cuff resting seated 
SBP from baseline to Day 84. Assuming an observed treatment difference of SBP changes 
between the KBP-5074 group and the placebo group is 5 mmHg, and a standard deviation of 
change from baseline of 15 mmHg, with 80 patients/group, the CI of the observed difference 
would not include 0. Assuming 10% to 15% dropout post randomization, 80 patients/group or a 
total of 240 patients would be needed for this Phase 2 study. Additional sample size estimates 
based on sample size needed per group to ensure that the observed 95% CI does not include 0 are 
shown below. No multiple comparison adjustment will be applied. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
23 
Sample Size Estimates 
Standard Deviation 
Observed Treatment Effect 
4 mmHg 
5 mmHg 
6 mmHg 
14 mmHg 
109 
70 
48 
15 mmHg 
125 
81 
56 
16 mmHg 
141 
91 
63 
Including approximately 10% to 15% dropout. 
Abbreviations: mmHg = millimeters of mercury 
 
SITES:  
Approximately 90 sites in North America, South America, Israel, and Europe 
SPONSOR: 
KBP BioSciences Co., Ltd. 
116 Village Blvd, Suite 210 
Princeton, NJ 08540 
United States  
Telephone: 609-531-0889 
Fax: 609-531-0892 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
24 
TABLE OF CONTENTS 
Signature Page ................................................................................................................................ 2 
Investigator Agreement ................................................................................................................... 3 
Summary of Changes – Amendment 2 ........................................................................................... 4 
Synopsis ........................................................................................................................................ 17 
Table of Contents .......................................................................................................................... 24 
List of Tables ................................................................................................................................ 28 
List of Figures ............................................................................................................................... 29 
List of Abbreviations and Definition of Terms............................................................................. 30 
1 Introduction and Background Information ............................................................................. 32 
2 Study Objectives ..................................................................................................................... 35 
2.1 
Primary Objective ......................................................................................................... 35 
2.2 
Secondary Objectives .................................................................................................... 35 
3 Study Description.................................................................................................................... 36 
3.1 
Summary of Study Design ............................................................................................ 36 
3.2 
Risk Management .......................................................................................................... 38 
3.2.1 Independent Data Monitoring Committee ......................................................... 38 
3.3 
Study Indication ............................................................................................................ 38 
4 Selection and Withdrawal of Patients ..................................................................................... 39 
4.1 
Inclusion Criteria ........................................................................................................... 39 
4.2 
Exclusion Criteria .......................................................................................................... 40 
4.3 
Withdrawal Criteria ....................................................................................................... 42 
5 Study Treatments .................................................................................................................... 44 
5.1 
Treatment Groups .......................................................................................................... 44 
5.2 
Rationale for Dosing ..................................................................................................... 44 
5.3 
Randomization and Blinding ......................................................................................... 44 
5.4 
Breaking the Blind ........................................................................................................ 45 
5.5 
Drug Supplies ................................................................................................................ 45 
5.5.1 Formulation and Packaging ............................................................................... 45 
5.5.2 Study Drug Preparation and Dispensing ........................................................... 46 
5.5.3 Study Drug Administration ............................................................................... 46 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
25 
5.5.4 Treatment Compliance ...................................................................................... 46 
5.5.5 Storage and Accountability ............................................................................... 46 
5.6 
Prior and/or Concomitant Medications and/or Procedures ........................................... 47 
5.6.1 Excluded Medications and/or Procedures ......................................................... 47 
5.6.2 Restricted Medications and/or Procedures ........................................................ 47 
5.6.3 Documentation of Prior and Concomitant Medication Use .............................. 47 
5.6.4 Management of Other Co-Morbidities .............................................................. 48 
6 Study Procedures .................................................................................................................... 49 
6.1 
Informed Consent .......................................................................................................... 49 
6.2 
Screening Visit (Visit 1) ................................................................................................ 49 
6.3 
Open-Label Placebo Run-In Period .............................................................................. 50 
6.3.1 Start of Open-Label Placebo Run-In Period (Visit 2) ....................................... 50 
6.3.2 End of Open-Label Placebo Run-In Period (Visit 3) ........................................ 51 
6.4 
Randomization and Treatment ...................................................................................... 52 
6.4.1 Day -1 (ABPM Visit) ........................................................................................ 52 
6.4.2 Day 1 (Visit 4) ±2 Days .................................................................................... 52 
6.4.3 Day 7 (Visit 5) ±2 Days .................................................................................... 53 
6.4.4 Day 14 (Visit 6) ±2 Days .................................................................................. 54 
6.4.5 Day 28 (Visit 7) ±3 Days .................................................................................. 55 
6.4.6 Day 40 (ABPM Visit) ±3 Days ......................................................................... 56 
6.4.7 Day 42 (Visit 8) ±3 Days .................................................................................. 56 
6.4.8 Day 56 (Visit 9) ±3 Days .................................................................................. 57 
6.4.9 Day 82 (ABPM Visit) ±3 Days ......................................................................... 58 
6.4.10 Day 84 (Visit 10) ±3 Days ................................................................................ 58 
6.5 
Day 112 (Visit 11) End of Study (Safety Follow-Up) ±5 Days .................................... 59 
6.6 
Early Termination Visit and Withdrawal Procedures ................................................... 60 
7 Efficacy Assessments.............................................................................................................. 62 
7.1 
Primary Efficacy Assessment ........................................................................................ 62 
7.2 
Secondary Efficacy Assessments .................................................................................. 62 
7.3 
Pharmacokinetic Assessment ........................................................................................ 62 
7.4 
Pharmacodynamic Assessment ..................................................................................... 62 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
26 
8 Safety Assessments ................................................................................................................. 64 
8.1 
Adverse Events .............................................................................................................. 64 
8.1.1 Adverse (Drug) Reaction .................................................................................. 65 
8.1.2 Unexpected Adverse Drug Reaction ................................................................. 65 
8.1.3 Assessment of Adverse Events by the Investigator .......................................... 65 
8.2 
Adverse Events of Special Interest ................................................................................ 66 
8.3 
Serious Adverse Events ................................................................................................. 67 
8.4 
Serious Adverse Event Reporting − Procedures for Investigators ................................ 67 
8.5 
Pregnancy Reporting ..................................................................................................... 68 
8.6 
Expedited Reporting ...................................................................................................... 68 
8.7 
Clinical Laboratory Evaluations .................................................................................... 69 
8.8 
Vital Signs ..................................................................................................................... 69 
8.9 
Electrocardiograms ........................................................................................................ 69 
8.10 Physical Examinations .................................................................................................. 69 
8.11 Height, Weight, and Body Mass Index ......................................................................... 69 
8.12 Safety Surveillance and Management of Serum Potassium Levels .............................. 70 
8.13 Safety Management of Serum Creatinine ..................................................................... 72 
8.14 Monitoring and Management of Blood Pressure .......................................................... 72 
9 Statistics .................................................................................................................................. 74 
9.1 
Analysis Populations ..................................................................................................... 74 
9.2 
Statistical Methods ........................................................................................................ 74 
9.2.1 Demographic and Baseline Comparability ....................................................... 74 
9.2.1.1 Study drug exposure, compliance, and concomitant therapies ........... 74 
9.2.2 Analysis of Efficacy .......................................................................................... 75 
9.2.2.1 Primary efficacy analysis .................................................................... 75 
9.2.2.2 Secondary efficacy analyses ............................................................... 75 
9.2.3 Analysis of Safety ............................................................................................. 75 
9.2.4 Analysis of Pharmacokinetics ........................................................................... 76 
9.2.5 Interim Analysis ................................................................................................ 76 
9.2.6 Independent Data Monitoring Committee ......................................................... 76 
9.2.7 Sample Size Determination ............................................................................... 76 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
27 
10 Data Management and Record Keeping ................................................................................. 78 
10.1 Data Management ......................................................................................................... 78 
10.1.1 Data Handling ................................................................................................... 78 
10.1.2 Computer Systems ............................................................................................. 78 
10.1.3 Data Entry ......................................................................................................... 78 
10.1.4 Medical Information Coding ............................................................................. 78 
10.1.5 Data Validation ................................................................................................. 78 
10.2 Record Keeping ............................................................................................................. 79 
11 Investigator Requirements and Quality Control ..................................................................... 80 
11.1 Ethical Conduct of the Study ........................................................................................ 80 
11.2 Institutional Review Board/Independent Ethics Committee ......................................... 80 
11.3 Informed Consent .......................................................................................................... 80 
11.4 Study Monitoring Requirements ................................................................................... 80 
11.5 Disclosure of Data ......................................................................................................... 81 
11.6 Retention of Records ..................................................................................................... 81 
11.7 Publication Policy ......................................................................................................... 81 
11.8 Financial Disclosure ...................................................................................................... 82 
12 Study Administrative Information .......................................................................................... 83 
12.1 Protocol Amendments ................................................................................................... 83 
12.2 Address List ................................................................................................................... 83 
12.2.1 Sponsor .............................................................................................................. 83 
12.2.2 Contract Research Organization ........................................................................ 83 
12.2.3 Drug Safety ....................................................................................................... 83 
12.2.4 Biological Specimens ........................................................................................ 83 
13 References ............................................................................................................................... 85 
Appendix A:  Schedule of Procedures .......................................................................................... 86 
Appendix B:  Clinical Laboratory Analytes ................................................................................. 89 
Appendix C:  Definition and Management of Hypertensive Crisis, Emergency, and Urgency ... 91 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
28 
LIST OF TABLES 
Table 1. 
Potassium Safety Monitoring – Reporting / Management of Hyperkalemia .............. 71 
Table 2. 
Sample Size Estimates ................................................................................................ 77 
 
 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
29 
LIST OF FIGURES 
Figure 1. Study Schematic.......................................................................................................... 37 
Figure 2. Diagnosis and Management of a Hypertensive Crisis ................................................ 92 
 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
30 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS  
Abbreviation 
Definition 
ABPM 
Ambulatory blood pressure monitoring 
AHA 
American Heart Association 
ANCOVA 
Analysis of covariance  
AUC 
Area under the plasma concentration versus time curve 
CFR 
Code of Federal Regulations 
CI 
Confidence interval 
CKD 
Chronic kidney disease 
Cmax 
Maximum observed plasma concentration 
CRA 
Clinical Research Associate 
CRP 
C-reactive protein 
CYP 
Cytochrome P450 
DBP 
Diastolic blood pressure 
ECG 
Electrocardiogram 
eCRF 
Electronic Case Report Form 
EDC 
Electronic data capture 
eGFR 
Estimated glomerular filtration rate 
ESC 
European Society of Cardiology 
ESH 
European Society of Hypertension 
FDA 
Food and Drug Administration 
FSH 
Follicle-stimulating hormone 
GCP 
Good Clinical Practice 
HbsAg 
Hepatitis B surface antigen 
HCV 
Hepatitis C virus 
HD 
Hemodialysis 
HIV 
Human immunodeficiency virus 
HR 
Heart rate 
HRT 
Hormone replacement therapy 
ICF 
Informed Consent Form 
ICH 
International Council for Harmonisation 
IDMC 
Independent data monitoring committee 
IEC 
Independent Ethics Committee 
IL-6 
Interleukin-6 
IRB 
Institutional Review Board 
IRT 
Interactive Response Technology 
ITT 
Intent-to-Treat 
MAP 
Mean arterial pressure 
MDRD 
Modification of Diet in Renal Disease 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
31 
Abbreviation 
Definition 
MR 
Mineralocorticoid receptor 
MRA 
Mineralocorticoid receptor antagonist 
NF 
National Formulary 
NT-proBNP 
N-terminal of the prohormone brain natriuretic peptide 
PD 
Pharmacodynamic 
PK 
Pharmacokinetic(s) 
PPK 
Population pharmacokinetic(s) 
QD 
Once daily 
QTcF 
QT interval corrected using Fridericia’s formula 
SAE 
Serious adverse event 
SBP 
Systolic blood pressure 
TEAE 
Treatment-emergent adverse event 
UACR 
Urine albumin-to-creatinine ratio 
ULN 
Upper limit of normal 
USP 
United States Pharmacopeia 
WOCBP 
Women of childbearing potential 
 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
32 
1 
INTRODUCTION AND BACKGROUND INFORMATION  
High blood pressure and hypertensive kidney damage are the leading cause of morbidity and 
mortality in the United States.1 Although considerable progress has been made in the treatment of 
hypertension and prevention of progression of renal insufficiency, the development of new therapy 
remains critical. Mineralocorticoid receptor (MR), a member of the steroid receptor family, has 
been shown to have a major pathophysiological role in the progression of kidney diseases, and the 
inhibition of MR signaling considerably reduces proteinuria in patients with chronic kidney 
disease (CKD).1,2,3 
Eplerenone is a highly selective aldosterone blocker developed for the treatment of hypertension 
and heart failure. However, MR antagonism with eplerenone causes a dose-dependent increase in 
serum potassium concentrations and is contraindicated in hypertensive patients with a creatinine 
clearance of <50 mL/min. Eplerenone should also be avoided in patients receiving potassium 
supplements or other potassium-sparing diuretics, such as amiloride and triamterene, particularly 
in patients with renal insufficiency, diabetes, and microalbuminuria.5 In addition, eplerenone 
causes mild dose-dependent increases in cholesterol, triglycerides, and serum creatinine, and a 
decrease in serum sodium.6 For this reason, a new MR antagonist with an improved efficacy and a 
low potential for adverse effects in patients with hypertension and moderate-to-severe CKD could 
potentially address this public health issue and an unmet medical need.  
KBP BioSciences Co., Ltd. (hereafter KBP BioSciences) is developing KBP-5074, a new 
investigational non-steroidal MR antagonist (MRA), for the treatment of hypertension and 
nephropathy, including diabetic and hypertensive nephropathy. It binds to the MR and blocks the 
binding of aldosterone, a component of the renin-angiotensin-aldosterone system. Aldosterone 
binds to MR in both epithelial (eg, kidney) and non-epithelial (eg, heart, blood vessels, and brain) 
tissues, and increases blood pressure through induction of sodium reabsorption and possibly other 
mechanisms. Thus, MRAs have the potential to block the deleterious effects of aldosterone on the 
cardiovascular system. 
As a non-steroidal MRA, KBP-5074 has the following potential advantages:  
• KBP-5074 selectively binds to recombinant human MRs relative to its binding to recombinant 
human glucocorticoid receptor, progesterone receptor, and androgen receptor. KBP-5074 has 
been demonstrated to have better efficacy in lowering blood pressure and renal protection in 
preclinical disease models than the benchmark compound eplerenone; and  
• KBP-5074 demonstrated a favorable safety profile compared to that of eplerenone; with no 
abnormal levels of potassium, cholesterol, triglycerides, or serum creatinine during the 
long-term toxicology studies. This suggests that KBP-5074 is potentially a safer and more 
efficacious MRA. 
KBP-5074 is an investigational agent, and limited data regarding its clinical safety profile are 
available at this time. Because KBP-5074 has the same mechanism of action as eplerenone, 
common adverse events associated with eplerenone may be relevant: dizziness, diarrhea, 
coughing, fatigue, and flu-like symptoms.  
A battery of pharmacology and toxicology studies including rat and dog acute toxicity studies, rat 
and dog 4-week and 13-week repeated dose toxicity studies, genotoxicity studies, and safety 
pharmacology studies were conducted to support the Investigational New Drug application for 
conducting clinical trials.  

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
33 
Further details regarding the preclinical safety studies of KBP-5074 and clinical development 
program can be found in the Investigator’s Brochure.7 
An open-label, parallel-group, single ascending dose study in healthy subjects to evaluate the 
safety, tolerability, and pharmacokinetics (PK) of KBP-5074 following oral administration and 
with a food-effect panel (Protocol KBP5074-1-001, NCT02228733) has been completed. Single 
oral doses of KBP-5074 at 0.5, 1.0, 5, 10, and 30 mg in the fasted state and 10 mg in the fed state 
were safe and well tolerated in healthy male and female subjects (a total of 46 subjects received 
KBP-5074). There were no drug-related adverse events reported during the study. There were no 
clinically meaningful trends noted based on safety laboratory assessments, including complete 
blood count and potassium levels, physical examinations, vital sign measurements, and 
electrocardiograms (ECGs) during the study. No evidence of bone marrow suppression was 
observed with increasing drug exposure. Specifically, no clinically meaningful trends of change 
in the complete blood counts (white blood cell, neutrophils, red blood cell, or platelets) with 
increasing drug exposure were observed. No gender difference in drug exposure was observed. 
The time to maximum observed concentration under fasted conditions varied from 4 hours to 
7 hours, suggesting relatively fast absorption of KBP-5074 following oral administration under 
fasted conditions. 
An open-label, multiple ascending dose study to evaluate the safety, tolerability, and PK of 
KBP-5074 in healthy subjects with a separate panel in patients with mild-to-moderate renal 
impairment (Protocol KBP5074-1-002, NCT02653014) has been completed. Administration of 
doses of 2.5 mg and 5 mg KBP-5074 once daily (QD) for 14 days in healthy subjects (n = 12), and 
0.5 mg and 2.5 mg QD for 56 days in mild-to-moderate CKD patients (n = 14) with proteinuria 
was safe and well tolerated overall. There was no apparent relationship between doses and the 
incidence or intensity of treatment-emergent adverse events (TEAEs). Hyperkalemia was observed 
in the high dose group for both healthy volunteers and mild-to-moderate CKD patients with 
proteinuria (high risk of hyperkalemia). No hyperkalemia was observed in the 0.5 mg dose group, 
other than 1 patient with a protocol inclusion violation of excessive serum potassium at baseline 
(5.1 mmol/L) and a history of acute kidney failure who had a hyperkalemia event (defined as a 
single observation of potassium > 5.6 mmol/L). All hyperkalemia events (other than in the patient 
with the protocol violation) were resolved without treatment. A clinically meaningful reduction of 
urine albumin-to-creatinine ratio (UACR) was observed in both treatment groups in Part 2 of the 
study. An apparent trend for clinically meaningful reduction of blood pressure was also observed, 
especially for patients with elevated blood pressure and renal impairment in Part 2 of the study. 
A Phase 1, open-label study in hemodialysis (HD) and non-HD patients with severe CKD to 
evaluate safety, tolerability, and PK of KBP-5074 following oral administration 
(Protocol KBP5074-1-003, NCT02837237) has been completed. Administration of a single dose 
of 0.5 mg KBP-5074 in HD patients (n = 6) and non-HD patients (n = 5) was safe and 
well tolerated overall. No severe TEAEs, serious adverse events (SAEs), deaths, or study 
discontinuations due to TEAEs occurred during the study.  
A Phase 1, open-label, partial crossover, single-dose study to evaluate the PK, dose 
proportionality, and safety/tolerability of tablet versus capsule formulations of KBP-5074 in 
healthy subjects (Protocol KBP5074-1-004, NCT03340753) has been completed. The study was 
designed to evaluate the PK of a new tablet formulation versus that of the current capsule 
formulation and help determine dose selection in future studies. Twenty healthy subjects were 
allocated 4:1 to either the crossover study groups (Cohort 1, 16 subjects) or to the 0.25-mg tablet 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
34 
single-dose treatment group (Cohort 2, 4 subjects). Subjects allocated to Cohort 1 were randomized 
1:1 to 0.5 mg tablet/capsule (8 subjects) or 1.0 mg tablet/capsule (8 subjects). Within Cohort 1, 
subjects were further randomized to receive a single dose of KBP-5074 (0.5 mg or 1.0 mg) in 
either capsule or tablet formulation in a 2-period crossover design that was separated by a 2-week 
washout period and concluded with a 2-week follow-up period. Subjects allocated to Cohort 2 
received a single dose of 0.25 mg in tablet formulation only. Cohort 2 provided additional data for 
the evaluation of dose exposure for the tablet formulation. The bioavailability of KBP-5074 tablet 
relative to KBP-5074 capsule was slightly higher: approximately 5% to 10% higher in area under 
the plasma concentration versus time curves (AUCs) and 15% to 20% higher in the maximum 
observed plasma concentration (Cmax). Dose proportionality of KBP-5074 tablet in the range of 
0.25 mg to 1.0 mg was demonstrated based on Hummel Criteria; dose proportionality of KBP-5074 
tablet in the range of 0.25 mg to 1.0 mg was not demonstrated but was close to dose proportionality 
according to Smith Criteria. Administration of KBP-5074 0.25 mg, 0.5 mg, and 1.0 mg tablet 
formulations, and 0.5 mg and 1.0 mg capsule formulations was generally safe and well tolerated, 
and the incidence of TEAEs was similar among treatments. 
The current study (Protocol KBP5074-2-001) is a randomized, double-blind, placebo-controlled, 
multi-center, Phase 2 study to assess the efficacy, safety, and PK of KBP-5074 0.25 mg QD and 
KBP-5074 0.5 mg QD versus placebo in patients with moderate-to-severe CKD (as defined by 
estimated glomerular filtration rate [eGFR]  15 and  44 mL/min/1.73 m2, based on the isotope 
dilution mass spectrometry traceable Modification of Diet in Renal Disease [MDRD] equation 
version 48) and uncontrolled hypertension (Grade 1 to 2 systolic hypertension – European Society 
of Cardiology [ESC]/European Society of Hypertension [ESH]).9 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
35 
2 
STUDY OBJECTIVES 
2.1 
Primary Objective 
The primary objective of this study is to evaluate the efficacy of KBP-5074 in patients with 
moderate-to-severe CKD on uncontrolled hypertension (eg, Grade 1 to 2 systolic hypertension – 
ESC/ESH) as determined by change in trough-cuff seated systolic blood pressure (SBP) from 
baseline to Day 84. 
2.2 
Secondary Objectives 
The secondary objectives of this study are the following: 
• To evaluate the change in trough-cuff seated diastolic blood pressure (DBP) from baseline to 
Day 84;  
• To evaluate the change in 24-hour mean, daytime mean, nighttime mean, morning mean, last 
6 hours of the dosing interval mean, SBP, DBP, mean arterial pressure (MAP), and heart 
rate (HR) from baseline to Day 84 in a subset of up to 40 patients per treatment group as 
measured by 24-hour ambulatory blood pressure monitoring (ABPM); 
• To evaluate the change and percent change in UACR from baseline to Day 84 (for patients 
with albuminuria [defined as UACR > 300 mg/g] or microalbuminuria [defined as UACR in 
the range of 30 mg/g to 300 mg/g]); 
• To evaluate the change in serum aldosterone and plasma renin levels from baseline to Day 84; 
• To evaluate the incidence of hyperkalemia (defined as serum potassium  5.6 mmol/L), 
incidence of severe hyperkalemia (defined as serum potassium  6.0 mmol/L), and incidence 
of patients with serum potassium > 5.0 mmol/L; 
• To evaluate the change in serum potassium levels from baseline to Day 84; 
• To evaluate the changes in eGFR and creatinine levels > 30% throughout the study period; and 
• To evaluate population PK (PPK) of KBP-5074. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
36 
3 
STUDY DESCRIPTION 
3.1 
Summary of Study Design 
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center study to assess the 
efficacy, safety, and PK of KBP-5074 in patients with moderate-to-severe CKD and uncontrolled 
hypertension (Grade 1 to 2 systolic hypertension – ESC/ESH).  
The study will enroll approximately 240 patients, randomized in a 1:1:1 ratio to 1 of 3 treatment 
groups (80 patients in each group): KBP-5074 0.25 mg QD, KBP-5074 0.5 mg QD, or placebo 
QD. Randomization will be stratified to balance enrollment for key variables that may influence 
safety and/or efficacy evaluations, including eGFR ( 30 versus < 30 mL/min/1.73 m2) and 
SBP ( 160 versus < 160 mmHg). Approximately 30% of patients enrolled in the study should 
have eGFR in the range of 15 to 29 mL/min/1.73 m2. The study will be approximately 5 months 
in duration with 84 days of double-blind treatment.  
The study will consist of up to a 4-week screening period, 2-week open-label (placebo) run-in 
period, 84-day double-blind treatment period, and a 4-week post-treatment safety follow-up 
period. 
Plasma samples for PK analysis will be collected from all patients. A total of 4 PK samples will 
be collected from each patient, including at Day 1 (prior to discharge), Day 14 pre-dose, Day 28 
pre-dose, and the End of Study Visit (Day 112)/Early Termination Visit. The pre-dose samples 
assume that patients will be dosed in the unit on the days above. If patients are not dosed in the 
unit on those days, a PK sample will be collected during each of these visits and the date and time 
of the last dose will be recorded. 
Safety will be assessed systematically, and an independent data monitoring committee (IDMC) 
will perform cumulative reviews of safety data at regular intervals during the study.  
Serum potassium levels, serum creatinine, and blood pressure will be closely monitored 
throughout the study and clinically significant changes will be reported as adverse events of special 
interest. 
At Screening and the end of the placebo run-in period (Visit 3), patients must have uncontrolled 
hypertension (Grade 1 to 2 systolic hypertension – ESC/ESH), defined as resting trough-cuff 
seated SBP  140 and  179 mmHg, based on the mean of at least 2 current consecutive blood 
pressure readings in the clinic and a serum potassium  4.8 mmol/L at Screening and the end of 
the placebo run-in period (Visit 3), and a mean (Visit 1 and Visit 3) eGFR  15 and 
 44 mL/min/1.73 m2.. 
In all cases, dose and frequency of concurrent antihypertensive medications are expected to be 
maintained without dose adjustment for 30 days prior to randomization in order to ensure that 
blood pressure is stable. In general, patients should not add or adjust dose and/or types of the 
antihypertensive medications they are receiving during the screening period and throughout the 
duration of the study (unless they develop symptomatic hypotension). The dose of diuretic may be 
adjusted based on developing or resolved edema, weight gain or loss, or pulmonary congestion. 
Patients will be advised to maintain their normal diet and avoid unhealthy levels of alcohol use or 
potassium-rich foods/drinks during the study period. No potassium supplements are permitted, 
unless clinically indicated to treat hypokalemia on an emergent basis until serum potassium values 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
37 
are within the normal range. The use of potassium-sparing diuretics is not permitted within 
3 months prior to Screening until the end of study assessments. Intermitted or chronic use of 
potassium-binding drugs is not permitted for 3 months prior to Screening until the end of study 
assessments.  
After completion of the screening period and the qualifying Screening Visit, patients who meet all 
eligibility criteria (except those criteria scheduled to be assessed after the Screening Visit), will 
enter the 2-week, open-label (placebo) run-in period. At the end of the run-in period (Visit 3), 
patients will be reassessed for eligibility, including persistence of uncontrolled hypertension and 
compliance with open-label placebo received during the run-in period and current antihypertensive 
medication. If a patient’s compliance is < 80% or > 120%, the patient will not be eligible for the 
study, and no further visits will be performed. 
If a patient is found to be ineligible during Screening, a single rescreening is allowed if the 
Investigator believes that the patient’s condition has changed, and the patient may be eligible 
before the rescreening tests. Please note that a new patient number should be assigned to any 
rescreened patient, and all of the procedures defined in the protocol for the Screening Visit and 
during the run-in period must be repeated. 
Patients who meet all eligibility criteria at Visit 4/Day 1 will be randomized (stratified based on 
eGFR  30 versus < 30 mL/min/1.73 m2 and SBP  160 versus < 160 mmHg) into the study on 
Day 1. All randomized patients will receive double-blind treatment for 84 days. Patients will be 
followed for 4 weeks for safety assessments after the last dose of study drug. Antihypertensive 
therapy may be modified if necessary during the safety assessment, following withdrawal of the 
study drug to maintain blood pressure control.  
A subset of up to 40 patients per treatment group who agree to participate in 24-hour ABPM and 
still meet eligibility criteria at the end of the run-in period (Visit 3) will undergo 24-hour ABPM 
on Day -1, Day 40, and Day 82.  
A study schematic is presented in Figure 1. 
Figure 1. Study Schematic 
 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
38 
3.2 
Risk Management 
3.2.1 
Independent Data Monitoring Committee 
An IDMC will be established to monitor this study. The IDMC will independently review the 
safety data and determine if it is safe to continue the study according to the protocol. An IDMC 
charter will be developed accordingly.  
The following will be closely monitored throughout the study: 
• Serum potassium levels (see Section 8.12 for details), 
• Serum creatinine (see Section 8.13 for details), and 
• Blood pressure (see Section 8.14 for details). 
3.3 
Study Indication 
Uncontrolled hypertension in patients with moderate-to-severe CKD. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
39 
4 
SELECTION AND WITHDRAWAL OF PATIENTS  
4.1 
Inclusion Criteria 
Patients who meet all of the following criteria will be eligible to participate in the study: 
1. Male or female, between 18 and 85 years of age, inclusive. The lower age limit may be higher 
if it is legally required in the participating country; 
2. Body mass index between 19 and 45 kg/m2, inclusive; 
3. Stage 3B/4 CKD (defined as eGFR  15 and  44 mL/min/1.73 m2, based on the isotope 
dilution mass spectrometry traceable MDRD equation version 4, according to central 
laboratory results at Screening [single retest is allowed]); 
4. Uncontrolled hypertension (Grade 1 to 2 systolic hypertension – ESC/ESH), defined as: 
o Resting trough-cuff seated SBP  140 and  179 mmHg based on the mean of at least 
2 current consecutive clinic blood pressure readings at Screening and at the end of the 
placebo run-in period (Visit 3); AND 
o Currently on 2 or more antihypertensive medications, which have been titrated upward as 
tolerated to recommended hypertension target doses (such as diuretics [except for 
potassium-sparing diuretics], renin-angiotensin system blockers, and/or calcium channel 
blockers. One of the antihypertensive medications must be high ceiling diuretic (loop or 
thiazide-like), unless there is a documented intolerance or contraindication to diuretic 
therapy. The doses of the antihypertensive medications should be stable without any dose 
adjustment during the 30 days prior to randomization; OR 
o Patients with uncontrolled hypertension and moderate-to-severe CKD with documented 
history of intolerance to multiple antihypertensive medications on fewer than 
2 antihypertensive medications; 
5. Serum potassium  4.8 mmol/L at both Screening and the end of the placebo run-in period. A 
single retest is allowed to exclude laboratory error or hemolyzed samples; 
6. Women of childbearing potential (WOCBP) must agree to use 2 medically accepted, effective 
methods of birth control during the study and for 90 days after the end of the study. Adequate 
methods of contraception are defined as those that result in a low failure rate (< 1% per year) 
when used consistently and correctly. Such methods include the use of oral contraceptives, 
other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable 
products), or mechanical products (such as an intrauterine diaphragm, condoms, or 
spermicides);  
o WOCBP are defined as women who are not surgically or chemically sterilized, including 
hysterectomy or bilateral oophorectomy (tubal ligation is not acceptable), and who are 
between menarche and 1-year post-menopause; and 
o Post-menopausal is defined as amenorrheic for at least 1 year, AND if aged under 60 years, 
have a serum follicle-stimulating hormone (FSH) level > 20 mIU/L. Women who are 
taking hormone replacement therapy (HRT) do not have to have FSH assessments, but the 
amenorrhea (before starting HRT) must have been naturally (spontaneously) occurring and 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
40 
have been accompanied by an appropriate clinical profile (eg, age appropriate and history 
of vasomotor symptoms); 
7. Males with partners who are WOCBP must agree to use condoms plus spermicide and their 
female partner must also be using contraception (eg, hormonal or intra-uterine device). This 
double contraception must be used from the first dose of study drug until at least 90 days after 
the last dose of study drug;  
8. Males must also refrain from donating sperm during the study and for 90 days after the last 
dose; and 
9. Capable of understanding the written informed consent, provide signed and witnessed written 
informed consent before any study-specific procedure, and agree to comply with protocol 
requirements. 
4.2 
Exclusion Criteria 
Patients who meet any of the following criteria will be excluded from participation in the study: 
1. Resting trough-cuff seated SBP  180 or < 140 mmHg, based on the mean of at least 2 current 
consecutive clinic blood pressure readings at Screening and the end of the placebo run-in 
period (Visit 3); 
2. Serum potassium > 4.8 mmol/L; 
3. Compliance with medications (including both open-label placebo and current antihypertensive 
medications) < 80% or > 120% during the run-in period (assessed at Visit 3); 
4. Currently on an MRA (eg, spironolactone or eplerenone) other than KBP-5074, or received 
any MRAs during the last 3 months prior to Screening, or currently on any potassium 
supplements; 
5. Chronic or intermittent use of a potassium binder for the treatment of hyperkalemia from 
3 months prior to Screening until the end of study assessments, including but not limited to 
calcium polystyrene sulfonates (eg, sorbisterit, calcium resonium), sodium polystyrene 
sulfonates (eg, kayexalate, anti-kalium sodium), and patiromer (eg, Veltassa™) and sodium 
zirconium cyclosilicate (eg, Lokelma™);  
6. Have routinely or chronically used or required potassium-sparing diuretics (eg, amiloride, 
triamterene) within 3 months prior to Screening until the end of study assessments; 
7. History of known/suspected contraindications, allergy, or intolerance to MRAs 
(eg, spironolactone, eplerenone) or has a known hypersensitivity to KBP-5074, other MRAs, 
or related compounds; 
8. Clinically significant hyperkalemia while on an angiotensin converting enzyme inhibitor, 
angiotensin receptor blocker, direct renin inhibitor, and/or MRA, requiring down-titration or 
discontinuation of above medication, or hospitalization for hyperkalemia within 3 months prior 
to Screening, or hyperkalemia > 5.6 mmol/L during the 2 weeks prior to Screening; 
9. History/diagnosis of renal artery stenosis or history/diagnosis of renovascular hypertension; 
10. Currently receiving HD, or peritoneal dialysis within 3 months prior to Screening, and those 
patients with an episode of acute kidney injury within 3 months of Screening; 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
41 
11. History of a renal transplant, or impending renal transplant; 
12. Acute decompensated heart failure including exacerbation of chronic heart failure manifested 
by signs and symptoms that may require hospitalization and/or intravenous diuretic therapy 
(New York Heart Association Class III to IV) within 3 months prior to Screening, or presence 
of hemodynamically significant valve diseases and/or other hemodynamically significant 
obstructive lesions of left ventricular outflow tract; 
13. Major cardiac, cerebral, and/or carotid artery diseases, including but not limited to acute 
coronary syndrome, myocardial infarction, stroke, and/or transient ischemic attack; major 
cardiovascular 
or 
percutaneous 
procedures 
including 
cardiac 
ablation, 
coronary 
revascularization, and carotid angioplasty within 6 months prior to Screening; OR 
o Cardiovascular conditions likely to require surgical or percutaneous intervention within 
6 months from Screening; 
14. History of clinically significant arrhythmia, including but not limited to any of the following: 
o Symptomatic bradycardia and/or symptomatic ventricular arrhythmia within 3 months 
prior to Screening;  
o Second- or third-degree heart block; or 
o New onset or untreated atrial fibrillation; Note: Patients with stable (6 months) 
asymptomatic rate controlled atrial fibrillation on appropriate therapy, which may include 
anticoagulation, are permitted. 
15. QT interval corrected using Fridericia’s formula (QTcF) > 450 ms for males or > 470 ms for 
females at Screening or Day 1; QTcF should be the average of the required triplicate set of 
ECGs at each timepoint;  
16. History of prolonged QT interval; 
17. History or family history of sudden cardiac death or long QT syndrome; 
18. History of cardiac transplant, on a heart transplant list, or has a left ventricular assistance 
device; 
19. History of clinically significant acute or chronic hepatitis (including infectious, metabolic, 
autoimmune, genetic, ischemic, or other forms), hepatocirrhosis, or hepatic tumors; 
20. History of gastrointestinal surgery that might affect absorption/oral bioavailability of oral 
antihypertensive therapies including KBP-5074; 
21. Clinically significant abnormal liver function test at Screening or the end of the run-in period 
(Visit 3), defined as aspartate aminotransferase or alanine aminotransferase > 3 × the upper 
limit of normal (ULN) or total bilirubin > 2 × ULN;  
o Note: Patients with total bilirubin > 2 × ULN and history of Gilbert’s syndrome may be 
included. 
22. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface 
antigen (HbsAg), or hepatitis C virus (HCV) antibody;  
23. History of malignancy in the past 5 years, with the exception of basal or resected cutaneous 
squamous cell carcinoma of the skin or carcinoma in situ, prostate cancer in situ with a normal 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
42 
prostate-specific antigen post treatment, cervical carcinoma in situ, gastric cancer in situ, colon 
cancer in situ adequately treated with no progression over the past 2 years;  
24. History of prescription drug abuse, illicit drug use, or alcohol abuse according to medical 
history within 6 months prior to Screening; 
25. A positive drug screen test (excluding a positive result secondary to a prescribed medication 
from a physician, or tetrahydrocannabinol) at Screening or the end of the run-in period 
(Visit 3);   
26. Female patients who are known to be pregnant or breastfeeding; 
27. Previously enrolled in any KBP-5074 study; 
28. Receipt of any other investigational product within 30 days or 5 half-lives (whichever is 
longer) prior to Screening; 
29. Use of any nutrients known to modulate cytochrome P450 (CYP)3A activity (based on the 
KBP-5074 metabolic pathway) or any strong or moderate inhibitors or inducers of CYP3A4, 
starting from 14 days prior to the first dose of study drug at Day 1 until the end of study 
assessments, including but not limited to the following: inhibitors, such as ketoconazole, 
miconazole, itraconazole, fluconazole, atazanavir, erythromycin, clarithromycin, ranitidine, 
and cimetidine, and inducers, such as rifampicin, rifabutin, glucocorticoids, carbamazepine, 
phenytoin, phenobarbital, and St. John’s wort; 
30. Has donated or lost a significant volume (> 500 mL) of blood or plasma within 30 days prior 
to Screening; 
31. An employee or family member of the Investigator or study site personnel; 
32. Unlikely to comply with the protocol requirements, instructions, and/or study-related 
restrictions (eg, uncooperative attitude, unavailable for follow up call, and/or improbability of 
completing the clinical study); and 
33. History of any other prior or concomitant clinical condition or acute and/or unstable systemic 
disease not listed above that, in the opinion of the Investigator, compromises patient inclusion, 
such as a history or presence of clinically decompensated or unstable cardiovascular, 
pulmonary, hepatic, gallbladder or biliary tract, hematologic, gastrointestinal, endocrine, 
immunologic, dermatologic, neurologic, or psychiatric disease, or concomitant morbidity of 
such severity that the patient is likely to die within 1 year from Screening. 
4.3 
Withdrawal Criteria 
Participation of a patient in this clinical study may be discontinued for any of the following 
reasons: 
• The patient withdraws consent or requests discontinuation from the study for any reason; 
• Significant protocol violation, including major protocol violations, such as taking prohibited 
medication or inability to comply with protocol procedure; 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
43 
• Any clinically significant adverse event, severe laboratory abnormality, intercurrent illness, or 
other medical condition that indicates to the Investigator that continued participation is not in 
the best interest of the patient, including: 
o Hypertensive Emergency; 
o Hyperkalemia defined in Table 1; or 
o Sustained increase in serum creatinine defined as an increase > 50% in serum creatinine 
from baseline and confirmed by a repeated test (see Section 8.13); 
• Pregnancy; 
• Termination of the study by the Sponsor or regulatory authority; or 
• Lost to follow-up. 
If a patient withdraws prematurely from the study due to the above criteria or any other reason, 
study staff should make every effort to complete the full panel of assessments scheduled for the 
Early Termination Visit (see Section 6.6). The reason for patient withdrawal must be documented 
in the electronic Case Report Form (eCRF). 
In the case of patients lost to follow-up, attempts to contact the patient must be made and 
documented in the patient’s medical records. 
Withdrawn patients will not be replaced. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
44 
5 
STUDY TREATMENTS 
5.1 
Treatment Groups 
After completion of the screening period and qualifying Screening Visit, patients who meet all 
eligibility criteria (except those criteria scheduled to be assessed after the Screening Visit) will 
enter a 2-week run-in period. During this time, all patients will be given open-label placebo.  
At the Day 1 Visit (scheduled within 4 ±2 days after the end of the run-in period [Visit 3]), eligible 
patients will be randomized by Interactive Response Technology (IRT) in a 1:1:1 ratio to the 
following treatment groups: 
• KBP-5074 0.25 mg QD orally,  
• KBP-5074 0.5 mg QD orally, or  
• Placebo QD orally 
The duration of the double-blind treatment period will be 84 days. Patients will remain on their 
stable antihypertensive medication (ie, no change in antihypertensive medication) throughout the 
entire study (including both the run-in and treatment periods). The dose of diuretic may be adjusted 
based on developing or resolved edema, weight gain or loss, or pulmonary congestion.  
5.2 
Rationale for Dosing 
As outlined in Section 1, based on data from preclinical and clinical efficacy, safety, PK, and 
relative bioavailability studies, KBP BioSciences has determined that 0.25 mg and 0.5 mg QD are 
the appropriate dosage for a planned Phase 2b study using the KBP-5074 tablet formulation. 
Clinical data were derived from 102 study subjects who participated in 4 Phase 1 studies, which 
included healthy normal subjects and patients with mild, moderate, and severe CKD, including 
patients receiving HD. Data show that study drug exposure, as expressed by several PK measures 
(AUC, Cmax), is similar for healthy subjects and patients with mild-to-moderate CKD. Exposure is 
increased, however, in patients with severe CKD (up to around 60% higher AUC and Cmax). 
Analysis of safety data from the Phase 1 studies suggests a possible correlation between increased 
exposure (AUC > 3000 ng*h/ml) and risk of hyperkalemia. The fragility of patients with severe 
CKD implies that sensitivity to drug and/or increases in free drug levels could substantially 
potentiate wanted and unwanted pharmaceutical effects in this population. These effects may be 
amplified with the use of the tablet formulation of KBP-5074, which has an approximately 
18% higher Cmax than the capsule formulation. 
5.3 
Randomization and Blinding 
This is a randomized, double-blind, placebo-controlled study. Patients will be randomized to one 
of the 3 treatment groups listed in Section 5.1. Randomization will be stratified based on the 
following values at baseline: 
• eGFR:  30 versus < 30 mL/min/1.73 m2, and 
• SBP:  160 versus < 160 mmHg. 
Individual treatment assignments will be blinded to the Sponsor, Investigator, study personnel, and 
patients throughout the course of the study. All individuals directly involved in the conduct of the 
study, including data management personnel, will remain blinded to treatment assignments. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
45 
5.4 
Breaking the Blind 
At all times, study personnel will attempt to safeguard the integrity of the blinding in order to 
minimize bias in the conduct of the study. Breaking of the blind should not occur except in the 
case of a medical emergency and should occur after discussion with the Medical Monitor. In such 
a case, the Investigator may access this information by contacting the Sponsor or its designee. If 
the blind is broken for an individual patient, the blinding should be preserved for the remainder of 
the patients throughout the duration of the study. In such a case, study personnel may be notified 
of that individual patient’s treatment assignment without jeopardizing study blinding for the 
overall study. 
If the blind is broken for a patient, the patient may or may not be asked to withdraw from the study. 
This decision will be based on Investigator consultation with the Medical Monitor. All patients 
will be asked to continue study visits to the end of the study whether or not they remain on study 
drug. If a patient must temporarily discontinue study drug, they may or may not be able to restart 
study drug. This decision will be based on Investigator consultation with the Medical Monitor. 
5.5 
Drug Supplies 
5.5.1 
Formulation and Packaging 
KBP-5074 tablets are supplied as 0.25 mg and 0.5 mg strengths for this study. The weight of the 
0.25 mg and 0.5 mg tablets are 109.5 mg and 111.0 mg, respectively. 
For the 0.25 mg strength, each unit of KBP-5074 drug product contains 0.23% KBP-5074 drug 
substance, 36.53% of microcrystalline cellulose PH101 (FMC, United States Pharmacopeia 
[USP]/National Formulary [NF]) as filler, 54.79% of lactose monohydrate (MEGGLE, USP/NF) 
as filler, 3.2% of croscarmellose sodium (FMC, USP/NF) as disintegrant agent, 2.28% of 
hydroxypropyl methyl cellulose E50 (DOW, USP/NF) as binder, 1.14% of sodium lauryl sulfate 
(BASF, USP/NF) as solubilizer, 0.91% magnesium stearate (GREVEN, USP/NF) as lubricant, and 
0.91% silicon dioxide (GRACE, USP/NF) as flow agent. 
For the 0.5 mg strength, each unit of KBP-5074 drug product contains 0.45% KBP-5074 drug 
substance, 36.04 % of microcrystalline cellulose PH101 (FMC, USP/NF) as filler, 54.05% of 
lactose monohydrate (MEGGLE, USP/NF) as filler, 3.15% of croscarmellose sodium (FMC, 
USP/NF) as disintegrant agent, 2.25% of hydroxypropyl methyl cellulose E50 (DOW, USP/NF) 
as binder, 2.25% of sodium lauryl sulfate (BASF, USP/NF) as solubilizer, 0.90% magnesium 
stearate (GREVEN, USP/NF) as lubricant, and 0.90% silicon dioxide (GRACE, USP/NF) as flow 
agent. 
For the placebo, each unit of placebo contains 36.20% of microcrystalline cellulose PH101 (FMC, 
USP/NF) as filler, 54.30% of lactose monohydrate (MEGGLE, USP/NF) as filler, 3.17% of 
croscarmellose sodium (FMC, USP/NF) as disintegrant agent, 2.26% of hydroxypropyl methyl 
cellulose E50 (DOW, USP/NF) as binder, 2.26% of sodium lauryl sulfate (BASF, USP/NF) as 
solubilizer, 0.90% magnesium stearate (GREVEN, USP/NF) as lubricant, and 0.90% silicon 
dioxide (GRACE, USP/NF) as flow agent. 
KBP-5074 tablets will be packaged in polypropylene bottles and closed by low-density 
polyethylene bottle caps with drying agent. Each polypropylene bottle will contain 35 tablets of 
drug product. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
46 
Each bottle will be labeled in English, the language appropriate to the investigational site 
participating in the study, and according to country-specific requirements. Label text will be 
approved according to the Sponsor’s agreed procedures. 
For all study drugs, a system of numbering in accordance with all requirements of Good 
Manufacturing Practice will be used, ensuring that each dose of study drug can be traced back to 
the respective bulk ware of the ingredients. A complete record of batch numbers and expiry dates 
of all study drug, as well as the labels, will be maintained in the Sponsor’s study file. 
5.5.2 
Study Drug Preparation and Dispensing 
Study drug will be dispensed as indicated on the Schedule of Procedures (Appendix A). At each 
visit where study drug is dispensed, the Investigator or designee will provide patients with 
sufficient study drug until the next scheduled dispensing visit. 
5.5.3 
Study Drug Administration 
Patients will take 1 tablet of either KBP-5074 0.25 mg, KBP-5074 0.5 mg, or placebo orally QD. 
5.5.4 
Treatment Compliance 
If a patient’s compliance with open-label placebo and/or current antihypertensive medications is 
< 80% or > 120% during the run-in period, the patient will not be eligible for the study, and no 
further visits will be performed. 
Patient compliance with study drug will be assessed by clinical site personnel via tablet counts of 
returned study drug and by questioning the patient, if necessary, at every post-randomization visit. 
A patient who is not compliant (has taken < 80% or > 120% of study drug) will be counseled at 
each visit on the importance of taking study drug as instructed. 
5.5.5 
Storage and Accountability 
Study drug must be stored in a secure area according to local regulations so that only the 
Investigator and other designated personnel have access to the study drug. The study drug should 
be stored at 15ºC to 25ºC and protected from light and moisture.  
The study drugs will be shipped to the investigational site. 
All unused and/or partially used study drug, except retention samples, must be returned to 
Worldwide Clinical Trials (Worldwide), if not authorized by the Sponsor to be destroyed at the 
site, prior to or upon completion or termination of the study. 
All study drugs returned to Worldwide must be accompanied by the appropriate documentation 
and be clearly identified. Returned supplies should be in their original containers. Empty bottles 
may be returned to Worldwide; however, it is the Investigator’s responsibility to arrange disposal 
of all empty containers. The return of unused study drug should be arranged by the assigned site 
monitor. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
47 
5.6 
Prior and/or Concomitant Medications and/or Procedures 
5.6.1 
Excluded Medications and/or Procedures 
Use of the following medications is not permitted during the study: 
• MRAs other than KBP-5074; 
• Potassium binders used for treatment of hyperkalemia from 3 months prior to Screening until 
the end of study assessments, including but not limited to calcium polystyrene (eg, sorbisterit, 
calcium resonium), sodium polystyrene (eg, kayexalate, anti-kalium sodium), patiromer 
(eg, Veltassa), and sodium zirconium cyclosilicate (eg, Lokelma); 
• Potassium-sparing diuretics (eg, amiloride, triamterene) within 3 months prior to Screening 
until the end of study assessments; 
• Potassium supplements (unless clinically indicated on an emergent basis to treat hypokalemia 
until serum potassium values are within the normal range [see Section 8.12]); 
• Hemodialysis/peritoneal dialysis; 
• Any nutrients known to modulate CYP3A activity (based on the KBP-5074 metabolic 
pathway) or any strong or moderate inhibitors or inducers of CYP3A4, starting from 14 days 
prior to the first dose of study drug at Day 1 until the end of study assessments, including, but 
not limited to the following: inhibitors, such as ketoconazole, miconazole, itraconazole, 
fluconazole, atazanavir, erythromycin, clarithromycin, ranitidine, and cimetidine, and 
inducers, such as rifampicin, rifabutin, systemic glucocorticoids (inhaled and topical 
permitted), carbamazepine, phenytoin, phenobarbital, and St. John’s wort; and 
• Any other medications (prescription drugs, herbal products, vitamins, minerals, and 
over-the-counter medications) that potentially increase serum potassium levels and/or cause 
toxicity to the kidney, including chronic or daily use of nonsteroidal anti-inflammatory drugs. 
These medications should be taken only if the Investigator considers these medically 
necessary. It is recommended that serum potassium levels and eGFR values should be closely 
monitored when patients take these medications. 
5.6.2 
Restricted Medications and/or Procedures 
Patients will be advised to maintain their normal diet and avoid unhealthy levels of alcohol use or 
potassium-rich foods/drinks during the study period. See Section 8.12 for more details on 
monitoring of potassium and management of elevated serum potassium. 
5.6.3 
Documentation of Prior and Concomitant Medication Use 
All medications in addition to the study drug (including vitamin preparations) that are taken by the 
patient during the study must be documented as concomitant medications and reported on the 
corresponding eCRF. The use of sodium bicarbonate or dosage adjustment for treatment of 
acidosis in CKD is permitted 
Patients must currently be on 2 or more antihypertensive medications, which have been titrated 
upward as tolerated to recommended hypertension target doses (such as diuretics [except for 
potassium sparing diuretics], renin angiotensin system blockers, and/or calcium channel blockers. 
One of the antihypertensive medications must be high ceiling diuretic (loop or thiazide-like), 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
48 
unless there is a documented intolerance or contraindication to diuretic therapy.  The doses of the 
antihypertensive medications should be stable without dose adjustment during the 30 days prior to 
randomization. The dose of diuretic may be adjusted based on developing or resolved edema, 
weight gain or loss, or pulmonary congestion.  
5.6.4 
Management of Other Co-Morbidities 
Patients who have additional co-morbidities (eg, diabetes, hyperlipidemia, and cardiovascular 
disease), should be managed and treated with glucose lowering, lipid lowering, and anti-platelet 
therapies as recommended by local clinical practice guidelines. It is highly recommended that any 
medical treatments for these co-morbidities will not be changed during the study period (from 
Screening to the End of Study Visit [Day 112]/Early Termination Visit). 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
49 
6 
STUDY PROCEDURES 
6.1 
Informed Consent 
Written informed consent for the study will be obtained from all patients before any 
protocol-specific procedures are carried out. 
6.2 
Screening Visit (Visit 1) 
The following procedures will be performed at Visit 1: 
• Obtain informed consent; 
• Assess eligibility criteria; 
• Record demographics and medical history; 
• Perform physical examination; 
• Record height and weight; 
• Calculate body mass index; 
• Contact IRT; 
• Perform 12-lead ECG in triplicate (patients should be resting in a supine position for at least 
10 minutes prior to assessment); 
• Obtain vital signs, including pulse rate, respiratory rate, and oral temperature; 
• Obtain blood pressure; 
o Note: Patients must have uncontrolled hypertension, defined as resting trough-cuff seated 
SBP  140 and  179 mmHg, based on the mean of at least 2 current consecutive blood 
pressure readings in the clinic; 
o Blood pressures are to be obtained according to the AHA recommendations for accurate 
blood pressure measurement. Patients should avoid smoking, caffeine, or exercise within 
30 minutes before measurement; empty his or her bladder; then sit quietly in a comfortable 
chair with back support for at least 10 minutes before measurement and remain still during 
the measurement. The patient’s limb should be supported to measure blood pressure to 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not take 
the measurement over clothes. Blood pressure measurements should be performed in the 
same arm throughout the study. Triplicate blood pressure measurements should be taken 
approximately 2 minutes apart with a validated, oscillometric upper arm blood pressure 
monitor. Trough cuff SBP and DBP values will be assessed based on the pre-defined blood 
pressure measurement guideline throughout the study. Pulse will be obtained 
simultaneously with blood pressure measurements; 
• Obtain blood samples for:  
o HIV, HbsAg, and HCV tests;  
o Clinical laboratory tests (central laboratory; see Appendix B); and 
o FSH (post-menopausal women only); 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
50 
• Obtain urine sample for: 
o Drug screen; 
o Urinalysis (central laboratory; see Appendix B); and 
o UACR; 
• Obtain serum sample for potassium (local and central laboratories); 
o Note: Serum potassium should be  4.8 mmol/L (local lab) to advance or continue to the 
placebo run-in Period;  
• Obtain serum sample for creatinine (central laboratory); 
• Obtain serum sample for pregnancy test (WOCBP only); and 
• Record adverse events and concomitant medications. 
If a patient is found to be not eligible during Screening, a single rescreening is allowed if the 
Investigator believes that the patient’s condition has changed, and the patient may be eligible 
before the rescreening tests. Please note that a new patient number should be assigned to any 
rescreened patients, and all of the procedures defined in the protocol for the Screening Visit must 
be repeated. 
6.3 
Open-Label Placebo Run-In Period 
6.3.1 
Start of Open-Label Placebo Run-In Period (Visit 2) 
The following procedures will be performed at Visit 2: 
• Record weight; 
• Contact IRT; 
• Obtain vital signs, including pulse rate, respiratory rate, and oral temperature; 
• Obtain blood pressure; 
o Note: Patients must have uncontrolled hypertension, defined as resting trough-cuff seated 
SBP  140 and  179 mmHg, based on the mean of at least 2 current consecutive blood 
pressure readings in the clinic; 
o Blood pressures are to be obtained according to the AHA recommendations for accurate 
blood pressure measurement. Patients should avoid smoking, caffeine, or exercise within 
30 minutes before measurement; empty his or her bladder; then sit quietly in a comfortable 
chair with back support for at least 10 minutes before measurement and remain still during 
the measurement. The patient’s limb should be supported to measure blood pressure to 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not take 
the measurement over clothes. Blood pressure measurements should be performed in the 
same arm throughout the study. Triplicate blood pressure measurements should be taken 
approximately 2 minutes apart with a validated, oscillometric upper arm blood pressure 
monitor. Trough cuff SBP and DBP values will be assessed based on the pre-defined blood 
pressure measurement guideline throughout the study. Pulse will be obtained 
simultaneously with blood pressure measurements; 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
51 
• Record adverse events and concomitant medications; and 
• Instruct patient on study drug and dispense study drug. 
o Note: Open-label placebo will be dispensed. 
6.3.2 
End of Open-Label Placebo Run-In Period (Visit 3) 
The following procedures will be performed at Visit 3: 
• Assess eligibility criteria; 
• Check study drug accountability and collect unused study drug;  
o Note: If a patient’s compliance to medications (including both open-label placebo and 
current antihypertensive medications) is < 80% or > 120%, he/she will not be eligible for 
the study and no further visits will be required; 
• Record weight; 
• Obtain vital signs, including pulse rate, respiratory rate, and oral temperature; 
• Obtain blood pressure; 
o Note: Patients must have uncontrolled hypertension, defined as resting trough-cuff seated 
SBP  140 and  179 mmHg, based on the mean of at least 2 current consecutive blood 
pressure readings in the clinic; 
o Blood pressures are to be obtained according to the AHA recommendations for accurate 
blood pressure measurement. Patients should avoid smoking, caffeine, or exercise within 
30 minutes before measurement; empty his or her bladder; then sit quietly in a comfortable 
chair with back support for at least 10 minutes before measurement and remain still during 
the measurement. The patient’s limb should be supported to measure blood pressure to 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not take 
the measurement over clothes. Blood pressure measurements should be performed in the 
same arm throughout the study. Triplicate blood pressure measurements should be taken 
approximately 2 minutes apart with a validated, oscillometric upper arm blood pressure 
monitor. Trough cuff SBP and DBP values will be assessed based on the pre-defined blood 
pressure measurement guideline throughout the study. Pulse will be obtained 
simultaneously with blood pressure measurements; 
• Obtain urine sample for drug screen; 
• Obtain serum sample for potassium (local and central laboratories); 
o Note: Serum potassium should be  4.8 mmol/L (local lab) to advance to randomization;  
• Obtain serum sample for creatinine (central laboratory); 
• Obtain blood sample for clinical chemistry (central laboratory; see Appendix B); 
• Record adverse events and concomitant medications; and 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
52 
• Instruct patient on 24-hour urine collection to be provided at Visit 4 and dispense laboratory 
materials for collection. 
6.4 
Randomization and Treatment  
6.4.1 
Day -1 (ABPM Visit) 
This visit is for patients undergoing 24-hour ABPM only (a subset of up to 40 patients per 
treatment group who agree to participate in 24-hour ABPM and still meet eligibility criteria at the 
end of the run-in period [Visit 3]) and is to be scheduled within 3 days of the end of the run-in 
period (Visit 3). 
The following procedure will be performed at the ABPM Visit: 
• 24-hour ABPM device placement and start. Blood pressure and HR measurements will be 
obtained every 20 minutes during the interval of 06:00:00 hours to 21:59:59 hours (to coincide 
with the daytime, awake period) and every 30 minutes during the interval of 22:00:00 hours to 
05:59:59 hours (to coincide with the nighttime, sleeping period). During the 24-hour ABPM 
recording period, a diary will be provided to the patient. Instructions and training will be 
provided to the site staff who will in turn provide instructions to the patient. 
6.4.2 
Day 1 (Visit 4) ±2 Days 
This visit is to be scheduled within 4 ±2 days after the end of the run-in period (Visit 3). 
The following procedures will be performed at Visit 4: 
• Assess eligibility: Patients must have uncontrolled hypertension, defined as resting trough-cuff 
seated SBP  140 and  179 mmHg, based on the mean of at least 2 current consecutive blood 
pressure readings in the clinic. Prior to randomization, all patients are to have a serum 
potassium  4.8 mmol/L at both Screening and the end of the placebo run-in period; and a 
mean (Visit 1 and Visit 3) eGFR  15 and  44 mL/min/1.73 m2. 
• Record weight; 
• Perform physical examination (pre-dose); 
• Perform 12-lead ECG in triplicate (patients should be resting in a supine position for at least 
10 minutes prior to assessment); 
• Obtain vital signs, including pulse rate, respiratory rate, and oral temperature; 
• Obtain blood pressure prior to study drug administration; 
o Blood pressures are to be obtained according to the AHA recommendations for accurate 
blood pressure measurement. Patients should avoid smoking, caffeine, or exercise within 
30 minutes before measurement; empty his or her bladder; then sit quietly in a comfortable 
chair with back support for at least 10 minutes before measurement and remain still during 
the measurement. The patient’s limb should be supported to measure blood pressure to 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not take 
the measurement over clothes. Blood pressure measurements should be performed in the 
same arm throughout the study. Triplicate blood pressure measurements should be taken 
approximately 2 minutes apart with a validated, oscillometric upper arm blood pressure 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
53 
monitor. Trough cuff SBP and DBP values will be assessed based on the pre-defined blood 
pressure measurement guideline throughout the study. Pulse will be obtained 
simultaneously with blood pressure measurements; 
• Obtain blood sample for clinical laboratory tests (central laboratory; see Appendix B); 
• Obtain urine sample for: 
o Urinalysis (central laboratory; see Appendix B); 
o Urine pregnancy test for WOCBP only (pre-dose);  
o UACR; and 
o 24-hour urine for UACR; 
• Obtain serum sample for potassium (local and central laboratories); 
• Obtain serum sample for creatinine (central laboratory); 
• Obtain plasma sample for PK from all patients (prior to patient’s release from the unit); 
• Obtain serum sample for aldosterone; 
• Obtain plasma sample for renin; 
• Obtain serum/plasma samples that will be stored at central laboratory for determination of 
various additional biomarkers, including but not limited to galectin-3, N-terminal of the 
prohormone brain natriuretic peptide (NT-proBNP), interleukin-6 (IL-6), collagen biomarkers, 
and C-reactive protein (CRP). The panel of biomarkers and time points for analysis will be 
determined prior to the database lock; 
• Record adverse events and concomitant medications; 
• After above laboratory and procedures, administer first dose of study drug and record time; 
• Instruct patient on study drug and dispense study drug; and 
• Download 24-hour ABPM readings at site (for a subset of up to 40 patients per treatment group 
who agree to participate in 24-hour ABPM and still meet eligibility criteria at the end of the 
run-in period [Visit 3] who undergo 24-hour ABPM). 
6.4.3 
Day 7 (Visit 5) ±2 Days 
The following procedures will be performed at Visit 5: 
• Record weight; 
• Perform 12-lead ECG in triplicate (patients should be resting in a supine position for at least 
10 minutes prior to assessment); 
• Obtain vital signs, including pulse rate, respiratory rate, and oral temperature; 
• Obtain blood pressure prior to study drug administration; 
o Blood pressures are to be obtained according to the AHA recommendations for accurate 
blood pressure measurement. Patients should avoid smoking, caffeine, or exercise within 
30 minutes before measurement; empty his or her bladder; then sit quietly in a comfortable 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
54 
chair with back support for at least 10 minutes before measurement and remain still during 
the measurement. The patient’s limb should be supported to measure blood pressure to 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not take 
the measurement over clothes. Blood pressure measurements should be performed in the 
same arm throughout the study. Triplicate blood pressure measurements should be taken 
approximately 2 minutes apart with a validated, oscillometric upper arm blood pressure 
monitor. Trough cuff SBP and DBP values will be assessed based on the pre-defined blood 
pressure measurement guideline throughout the study. Pulse will be obtained 
simultaneously with blood pressure measurements; 
• Obtain blood sample for clinical laboratory tests (central laboratory; see Appendix B); 
• Obtain urine sample for: 
o Urinalysis (central laboratory; see Appendix B); and 
o UACR; 
• Obtain serum sample for potassium (local and central laboratories); 
• Obtain serum sample for creatinine (central laboratory); 
• Record adverse events and concomitant medications; 
• Check study drug accountability and collect unused study drug; 
• Administer daily dose of study drug and record time; and 
• Instruct patient on study drug and re-dispense study drug. 
6.4.4 
Day 14 (Visit 6) ±2 Days 
The following procedures will be performed at Visit 6: 
• Record weight; 
• Obtain vital signs including pulse rate, respiratory rate, and oral temperature; 
• Obtain blood pressure prior to study drug administration; 
o Blood pressures are to be obtained according to the AHA recommendations for accurate 
blood pressure measurement. Patients should avoid smoking, caffeine, or exercise within 
30 minutes before measurement; empty his or her bladder; then sit quietly in a comfortable 
chair with back support for at least 10 minutes before measurement and remain still during 
the measurement. The patient’s limb should be supported to measure blood pressure to 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not take 
the measurement over clothes. Blood pressure measurements should be performed in the 
same arm throughout the study. Triplicate blood pressure measurements should be taken 
approximately 2 minutes apart with a validated, oscillometric upper arm blood pressure 
monitor. Trough cuff SBP and DBP values will be assessed based on the pre-defined blood 
pressure measurement guideline throughout the study. Pulse will be obtained 
simultaneously with blood pressure measurements; 
• Obtain blood sample for clinical laboratory tests (central laboratory; see Appendix B); 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
55 
• Obtain urine sample for: 
o Urinalysis (central laboratory; see Appendix B); and 
o UACR; 
• Obtain serum sample for potassium (local and central laboratories); 
• Obtain serum sample for creatinine (central laboratory); 
• Obtain plasma sample for PK from all patients (pre-dose). If patients are not dosed in the unit 
on this day, a PK sample will be collected, and the date and time of the last dose will be 
recorded; 
• Record adverse events and concomitant medications; 
• Check study drug accountability and collect unused study drug; 
• Administer daily dose of study drug and record time; and 
• Instruct patient on study drug and re-dispense study drug. 
6.4.5 
Day 28 (Visit 7) ±3 Days 
The following procedures will be performed at Visit 7: 
• Record weight; 
• Contact IRT; 
• Obtain vital signs including pulse rate, respiratory rate, and oral temperature; 
• Obtain blood pressure prior to study drug administration; 
o Blood pressures are to be obtained according to the AHA recommendations for accurate 
blood pressure measurement. Patients should avoid smoking, caffeine, or exercise within 
30 minutes before measurement; empty his or her bladder; then sit quietly in a comfortable 
chair with back support for at least 10 minutes before measurement and remain still during 
the measurement. The patient’s limb should be supported to measure blood pressure to 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not take 
the measurement over clothes. Blood pressure measurements should be performed in the 
same arm throughout the study. Triplicate blood pressure measurements should be taken 
approximately 2 minutes apart with a validated, oscillometric upper arm blood pressure 
monitor. Trough cuff SBP and DBP values will be assessed based on the pre-defined blood 
pressure measurement guideline throughout the study. Pulse will be obtained 
simultaneously with blood pressure measurements; 
• Obtain blood sample for clinical laboratory tests (central laboratory; see Appendix B); 
• Obtain urine sample for: 
o Urinalysis (central laboratory; see Appendix B); and 
o UACR; 
• Obtain serum sample for potassium (local and central laboratories); 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
56 
• Obtain serum sample for creatinine (central laboratory); 
• Obtain plasma sample for PK from all patients (pre-dose). If patients are not dosed in the unit 
on this day, a PK sample will be collected, and the date and time of the last dose will be 
recorded; 
• Record adverse events and concomitant medications; 
• Check study drug accountability and collect unused study drug; 
• Instruct patient on study drug and re-dispense study drug; 
• Administer daily dose of study drug and record time; and 
• Instruct patient on 24-hour urine collection to be provided at Visit 8 and dispense laboratory 
materials for collection. 
6.4.6 
Day 40 (ABPM Visit) ±3 Days  
This visit is for 24-hour ABPM patients only (a subset of up to 40 patients per treatment group 
who agree to participate in 24-hour ABPM and still meet eligibility criteria at the end of the run-in 
period [Visit 3]). 
The following procedure will be performed at the ABPM Visit: 
• 24-hour ABPM device placement and start. Blood pressure and HR measurements will be 
obtained every 20 minutes during the interval of 06:00:00 hours to 21:59:59 hours (to coincide 
with the daytime, awake period) and every 30 minutes during the interval of 22:00:00 hours to 
05:59:59 hours (to coincide with the nighttime, sleeping period). During the 24-hour ABPM 
recording period, a diary will be provided to the patient. Instructions and training will be 
provided to the site staff, who will in turn provide instructions to the patient. 
6.4.7 
Day 42 (Visit 8) ±3 Days 
The following procedures will be performed at Visit 8: 
• Record weight; 
• Obtain vital signs including pulse rate, respiratory rate, and oral temperature; 
• Obtain blood pressure prior to study drug administration; 
o Blood pressures are to be obtained according to the AHA recommendations for accurate 
blood pressure measurement. Patients should avoid smoking, caffeine, or exercise within 
30 minutes before measurement; empty his or her bladder; then sit quietly in a comfortable 
chair with back support for at least 10 minutes before measurement and remain still during 
the measurement. The patient’s limb should be supported to measure blood pressure to 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not take 
the measurement over clothes. Blood pressure measurements should be performed in the 
same arm throughout the study. Triplicate blood pressure measurements should be taken 
approximately 2 minutes apart with a validated, oscillometric upper arm blood pressure 
monitor. Trough cuff SBP and DBP values will be assessed based on the pre-defined blood 
pressure measurement guideline throughout the study. Pulse will be obtained 
simultaneously with blood pressure measurements; 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
57 
• Obtain blood sample for clinical laboratory tests (central laboratory; see Appendix B); 
• Obtain urine sample for: 
o Urinalysis (central laboratory; see Appendix B); 
o UACR; and 
o 24-hour urine for UACR; 
• Obtain serum sample for potassium (local and central laboratories); 
• Obtain serum sample for creatinine (central laboratory); 
• Record adverse events and concomitant medications; 
• Check study drug accountability and collect unused study drug; 
• Instruct patient on study drug and re-dispense study drug; 
• Administer daily dose of study drug and record time; and 
• Download 24-hour ABPM readings at site (for a subset of up to 40 patients per treatment group 
who agree to participate in 24-hour ABPM and still meet eligibility criteria at the end of the 
run-in period [Visit 3] who undergo 24-hour ABPM). 
6.4.8 
Day 56 (Visit 9) ±3 Days 
The following procedures will be performed at Visit 9: 
• Record weight; 
• Contact IRT; 
• Obtain vital signs including pulse rate, respiratory rate, and oral temperature; 
• Obtain blood pressure prior to study drug administration; 
o Blood pressures are to be obtained according to the AHA recommendations for accurate 
blood pressure measurement. Patients should avoid smoking, caffeine, or exercise within 
30 minutes before measurement; empty his or her bladder; then sit quietly in a comfortable 
chair with back support for at least 10 minutes before measurement and remain still during 
the measurement. The patient’s limb should be supported to measure blood pressure to 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not take 
the measurement over clothes. Blood pressure measurements should be performed in the 
same arm throughout the study. Triplicate blood pressure measurements should be taken 
approximately 2 minutes apart with a validated, oscillometric upper arm blood pressure 
monitor. Trough cuff SBP and DBP values will be assessed based on the pre-defined blood 
pressure measurement guideline throughout the study. Pulse will be obtained 
simultaneously with blood pressure measurements; 
• Obtain blood sample for clinical laboratory tests (central laboratory; see Appendix B); 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
58 
• Obtain urine sample for: 
o Urinalysis (central laboratory; see Appendix B); and 
o UACR; 
• Obtain serum sample for potassium (local and central laboratories); 
• Obtain serum sample for creatinine (central laboratory); 
• Record adverse events and concomitant medications; 
• Check study drug accountability and collect unused study drug; 
• Instruct patient on study drug and re-dispense study drug; 
• Administer daily dose of study drug and record time; and 
• Instruct patient on 24-hour urine collection to be provided at Visit 10 and dispense laboratory 
materials for collection. 
6.4.9 
Day 82 (ABPM Visit) ±3 Days 
This visit is for 24-hour ABPM patients only (a subset of up to 40 patients per treatment group 
who agree to participate in 24-hour ABPM and still meet eligibility criteria at the end of the run-in 
period [Visit 3]). 
The following procedure will be performed at the ABPM Visit: 
• 24-hour ABPM device placement and start. Blood pressure and HR measurements will be 
obtained every 20 minutes during the interval of 06:00:00 hours to 21:59:59 hours (to coincide 
with the daytime, awake period), and every 30 minutes during the interval of 22:00:00 hours 
to 05:59:59 hours (to coincide with the nighttime, sleeping period). During the 24-hour ABPM 
recording period, a diary will be provided to the patient. Instructions and training will be 
provided to the site staff, who will in turn provide instructions to the patient. 
6.4.10 
Day 84 (Visit 10) ±3 Days 
The following procedures will be performed at Visit 10: 
• Perform physical examination; 
• Record weight; 
• Calculate body mass index; 
• Obtain vital signs including pulse rate, respiratory rate, and oral temperature; 
• Obtain blood pressure; 
o Blood pressures are to be obtained according to the AHA recommendations for accurate 
blood pressure measurement. Patients should avoid smoking, caffeine, or exercise within 
30 minutes before measurement; empty his or her bladder; then sit quietly in a comfortable 
chair with back support for at least 10 minutes before measurement and remain still during 
the measurement. The patient’s limb should be supported to measure blood pressure to 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not take 
the measurement over clothes. Blood pressure measurements should be performed in the 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
59 
same arm throughout the study. Triplicate blood pressure measurements should be taken 
approximately 2 minutes apart with a validated, oscillometric upper arm blood pressure 
monitor. Trough cuff SBP and DBP values will be assessed based on the pre-defined blood 
pressure measurement guideline throughout the study. Pulse will be obtained 
simultaneously with blood pressure measurements; 
• Obtain blood sample for clinical laboratory tests (central laboratory; see Appendix B); 
• Obtain urine sample for: 
o Urinalysis (central laboratory; see Appendix B); 
o UACR; and 
o 24-hour urine for UACR; 
• Obtain serum sample for aldosterone; 
• Obtain plasma sample for renin; 
• Obtain serum sample for potassium (local and central laboratories); 
• Obtain serum sample for creatinine (central laboratory); 
• Obtain serum/plasma samples that will be stored at the central laboratory for determination of 
various additional biomarkers, including but not limited to galectin-3, NT-proBNP, IL-6, 
collagen biomarkers and CRP. The panel of biomarkers and time points for analysis will be 
determined prior to the database lock; 
• Record adverse events and concomitant medications; 
• Check study drug accountability and collect unused study drug; and 
• Download 24-hour ABPM readings at site (for a subset of up to 40 patients per treatment group 
who agree to participate in 24-hour ABPM and still meet eligibility criteria at the end of the 
run-in period [Visit 3] who undergo 24-hour ABPM). 
6.5 
Day 112 (Visit 11) End of Study (Safety Follow-Up) ±5 Days 
The following procedures will be performed at the End of Study (Safety Follow-Up) Visit 
(Visit 11): 
• Record weight; 
• Perform physical examination; 
• Perform 12-lead ECG in triplicate (patients should be resting in a supine position for at least 
10 minutes prior to assessment); 
• Obtain vital signs including pulse rate, respiratory rate, and oral temperature; 
• Obtain blood pressure; 
o Blood pressures are to be obtained according to the AHA recommendations for accurate 
blood pressure measurement. Patients should avoid smoking, caffeine, or exercise within 
30 minutes before measurement; empty his or her bladder; then sit quietly in a comfortable 
chair with back support for at least 10 minutes before measurement and remain still during 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
60 
the measurement. The patient’s limb should be supported to measure blood pressure to 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not take 
the measurement over clothes. Blood pressure measurements should be performed in the 
same arm throughout the study. Triplicate blood pressure measurements should be taken 
approximately 2 minutes apart with a validated, oscillometric upper arm blood pressure 
monitor. Trough cuff SBP and DBP values will be assessed based on the pre-defined blood 
pressure measurement guideline throughout the study. Pulse will be obtained 
simultaneously with blood pressure measurements; 
• Obtain blood sample for clinical laboratory tests (central laboratory; see Appendix B); 
• Obtain urine sample for: 
o Urinalysis (central laboratory; see Appendix B); and 
o UACR; 
• Obtain plasma sample for PK from all patients; 
• Obtain serum sample for pregnancy test (WOCBP only); 
• Obtain serum sample for potassium (local and central laboratories); 
• Obtain serum sample for creatinine (central laboratory); and 
• Record adverse events and concomitant medications. 
6.6 
Early Termination Visit and Withdrawal Procedures 
For patients who are withdrawn from the study prior to completion, the following procedures will 
be performed at an Early Termination Visit (as early as feasible after discontinuation of the study 
drug):  
• Perform physical examination; 
• Record weight; 
• Contact IRT; 
• Perform 12-lead ECG in triplicate (patients should be resting in a supine position for at least 
10 minutes prior to assessment); 
• Obtain vital signs including pulse rate, respiratory rate, and oral temperature; 
• Obtain blood pressure; 
o Blood pressures are to be obtained according to the AHA recommendations for accurate 
blood pressure measurement. Patients should avoid smoking, caffeine, or exercise within 
30 minutes before measurement; empty his or her bladder; then sit quietly in a comfortable 
chair with back support for at least 10 minutes before measurement and remain still during 
the measurement. The patient’s limb should be supported to measure blood pressure to 
ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not take 
the measurement over clothes. Blood pressure measurements should be performed in the 
same arm throughout the study. Triplicate blood pressure measurements should be taken 
approximately 2 minutes apart with a validated, oscillometric upper arm blood pressure 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
61 
monitor. Trough cuff SBP and DBP values will be assessed based on the pre-defined blood 
pressure measurement guideline throughout the study. Pulse will be obtained 
simultaneously with blood pressure measurements; 
• Obtain blood sample for clinical laboratory tests (central laboratory; see Appendix B); 
• Obtain urine sample for: 
o Urinalysis (central laboratory; see Appendix B); and 
o UACR; 
• Obtain plasma sample for PK from all patients; 
• Obtain serum sample for aldosterone; 
• Obtain plasma sample for renin; 
• Obtain serum/plasma samples that will be stored at the central laboratory for determination of 
various additional biomarkers, including but not limited to galectin-3, NT-proBNP, IL-6, 
collagen biomarkers, and CRP. The panel of biomarkers and time points for analysis will be 
determined prior to the database lock; 
• Obtain serum sample for pregnancy test (WOCBP only); 
• Obtain serum sample for potassium (local and central laboratories); 
• Obtain serum sample for creatinine (central laboratory); 
• Record adverse events and concomitant medications; 
• Check study drug accountability and collect unused study drug; and 
• Download 24-hour ABPM readings at site if a patient has completed the 24-hour ABPM 
recording since their last visit (for a subset of up to 40 patients per treatment group who agree 
to participate in 24-hour ABPM and still meet eligibility criteria at the end of the run-in period 
[Visit 3] who undergo 24-hour ABPM). 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
62 
7 
EFFICACY ASSESSMENTS 
7.1 
Primary Efficacy Assessment 
The primary efficacy variable is the change in trough-cuff resting seated SBP from baseline to 
Day 84. 
Blood pressure must be measured in triplicate prior to study drug administration at the visits 
indicated on the Schedule of Procedures (Appendix A). Trough-cuff SBP values will be assessed 
based on the pre-defined blood pressure measure guideline throughout the study.  
7.2 
Secondary Efficacy Assessments 
Twenty-four-hour ABPM monitoring will be assessed at the visits indicated on the Schedule of 
Procedures (Appendix A) in a subset of up to 40 patients per treatment group. At the end of the 
run-in period (Visit 3), ABPM will only be assessed for those patients who agree to participate in 
24-hour ABPM and still meet all of the eligibility criteria. Blood pressure and HR measurements 
will be obtained every 20 minutes during the interval of 06:00:00 hours to 21:59:59 hours (to 
coincide with the daytime, awake period) and every 30 minutes during the interval of 
22:00:00 hours to 05:59:59 hours (to coincide with the nighttime, sleeping period). 
During the 24-hour ABPM recording period, a diary will be provided to the patient. Instructions 
and training will be provided to the site staff, who will in turn provide instructions to the patient. 
The key secondary efficacy variables include the following: 
• Change in trough-cuff seated DBP from baseline to Day 84; 
Note: Blood pressure must be measured in triplicate prior to study drug administration at the visits 
indicated on the Schedule of Procedures (Appendix A). Trough-cuff DBP values will be assessed 
based on the pre-defined blood pressure measure guideline throughout the study. 
• Change in 24-hour mean, daytime mean, nighttime mean, morning mean, last 6 hours of the 
dosing interval mean, SBP, DBP, MAP, and HR from baseline to Day 84 as measured by 
24-hour ABPM in a subset of up to 40 patients per treatment group; and 
• Change and percent change in UACR from baseline to Day 84 (for patients with albuminuria 
[defined as UACR >300 mg/g] or microalbuminuria [defined as UACR in the range of 30 mg/g 
to 300 mg/g]). 
7.3 
Pharmacokinetic Assessment 
Plasma samples for PK analyses will be collected from all patients at the visits indicated on the 
Schedule of Procedures (Appendix A). 
7.4 
Pharmacodynamic Assessment 
The pharmacodynamic (PD) variable of this study is the change in levels of serum aldosterone and 
plasma renin from baseline to Day 84. Serum samples for aldosterone and plasma samples for 
renin will be collected at the visits indicated on the Schedule of Procedures (Appendix A). 
Serum/plasma samples will be stored at the central laboratory for determination of various 
additional biomarkers, including but not limited to galectin-3, NT-proBNP, IL-6, collagen 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
63 
biomarkers, and CRP. The panel of biomarkers and time points for analysis will be determined 
prior to the database lock. 
 
 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
64 
8 
SAFETY ASSESSMENTS 
Safety variables will include adverse events, vital signs (pulse rate, respiratory rate, and oral 
temperature), clinical laboratory findings, 12-lead ECGs, and physical examination findings. 
The following serum potassium/hyperkalemia-related parameters and renal function-related 
parameters will be collected and evaluated: 
• Incidence of hyperkalemia (defined as serum potassium  5.6 mmol/L), incidence of severe 
hyperkalemia (defined as serum potassium  6.0 mmol/L), and incidence of patients with 
serum potassium > 5.0 mmol/L; 
• Change in serum potassium level from baseline to Day 84; and 
• Change in eGFR and creatinine levels > 30% throughout the study period. 
8.1 
Adverse Events 
An adverse event is defined as any untoward medical occurrence in a clinical investigation patient 
administered a pharmaceutical product, which does not necessarily have a causal relationship with 
this treatment. An adverse event can therefore be any unfavorable and/or unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of an investigational medicinal product, whether or not related to the investigational medicinal 
product. All adverse events, including observed or volunteered problems, complaints, or 
symptoms, are to be recorded on the appropriate eCRF. 
Adverse events, which include clinical laboratory test variables, will be monitored and 
documented from the time of informed consent until study participation is complete. Patients 
should be instructed to report any adverse event that they experience to the Investigator. Beginning 
with the Screening Visit, Investigators should make an assessment for adverse events at each visit 
and record the event on the appropriate adverse event eCRF. 
Wherever possible, a specific disease or syndrome rather than individual associated signs and 
symptoms should be identified by the Investigator and recorded on the eCRF. However, if an 
observed or reported sign or symptom is not considered a component of a specific disease or 
syndrome by the Investigator, it should be recorded as a separate adverse event on the eCRF. 
Additionally, the condition that led to a medical or surgical procedure (eg, surgery, endoscopy, 
tooth extraction, or transfusion) should be recorded as an adverse event, not the procedure.  
Any medical condition already present at Screening should not be reported as an adverse event 
unless the medical condition or signs or symptoms present at baseline changes in severity or 
seriousness at any time during the study. In this case, it should be reported as an adverse event. 
Clinically significant abnormal laboratory or other examination (eg, ECG) findings that are 
detected during the study or are present at Screening and significantly worsen during the study 
should be reported as adverse events. The Investigator will exercise his or her medical and 
scientific judgment in deciding whether an abnormal laboratory finding or other abnormal 
assessment is clinically significant. Clinically significant abnormal laboratory values occurring 
during the clinical study will be followed until repeat tests return to normal, stabilize, or are no 
longer clinically significant. Any abnormal test that is determined to be an error does not require 
reporting as an adverse event. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
65 
8.1.1 
Adverse (Drug) Reaction 
All noxious and unintended responses to a medicinal product related to any dose should be 
considered an adverse drug reaction. “Responses” to a medicinal product means that a causal 
relationship between a medicinal product and an adverse event is at least a reasonable possibility, 
ie, the relationship cannot be ruled out. 
8.1.2 
Unexpected Adverse Drug Reaction 
An unexpected adverse drug reaction is defined as an adverse reaction, the nature or severity of 
which is not consistent with the applicable product information. For KBP-5074, the reference 
safety information is included in Section 5.1.6 of the Investigator’s Brochure7 currently in force. 
The reference safety information will be reviewed yearly, and the periodicity of the review will be 
harmonized with the reporting period of the Development Safety Update Report. 
8.1.3 
Assessment of Adverse Events by the Investigator 
The Investigator will assess the severity (intensity) of each adverse event as mild, moderate, or 
severe, and will also categorize each adverse event as to its potential relationship to study drug 
using the categories of yes or no. 
Assessment of Severity: 
Mild – An event that is easily tolerated and generally not interfering with normal daily activities. 
Moderate – An event that is sufficiently discomforting to interfere with normal daily activities. 
Severe – An event that is incapacitating with inability to work or perform normal daily activities. 
Causality Assessment: 
The relationship of an adverse event to the administration of the study drug is to be assessed 
according to the following definitions: 
No (unrelated, not related, no relation) – The time course between the administration of study drug 
and the occurrence or worsening of the adverse event rules out a causal relationship and another 
cause (concomitant drugs, therapies, complications, etc.) is suspected. 
Yes (related) – The time course between the administration of study drug and the occurrence or 
worsening of the adverse event is consistent with a causal relationship and no other cause 
(concomitant drugs, therapies, complications, etc.) can be identified. 
The definition implies a reasonable possibility of a causal relationship between the event and the 
study drug. This means that there are facts (evidence) or arguments to suggest a causal relationship. 
The following factors should also be considered: 
• The temporal sequence from study drug administration- 
o The event should occur after the study drug is given. The length of time from study drug 
exposure to event should be evaluated in the clinical context of the event. 
• Underlying, concomitant, intercurrent diseases- 
o Each report should be evaluated in the context of the natural history and course of the 
disease being treated and any other disease the patient may have. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
66 
• Concomitant drug- 
o The other drugs the patient is taking or the treatment the patient receives should be 
examined to determine whether any of them might be recognized to cause the event in 
question. 
• Known response pattern for this class of study drug- 
o Clinical and/or preclinical data may indicate whether a particular response is likely to be a 
class effect. 
• Exposure to physical and/or mental stresses- 
o The exposure to stress might induce adverse changes in the recipient and provide a logical 
and better explanation for the event. 
• The pharmacology and PK of the study drug- 
o The known pharmacologic properties (absorption, distribution, metabolism, and excretion) 
of the study drug should be considered. 
8.2 
Adverse Events of Special Interest 
The following adverse events of special interest must be reported to the Sponsor within 24 hours 
of the Investigator’s awareness, even if not meeting the definition of an SAE: 
• Hyperkalemia; 
o Mild hyperkalemia defined as serum potassium 5.0 mmol/L to 5.5 mmol/L (central or local 
laboratory); 
o Moderate hyperkalemia defined as serum potassium 5.6 mmol/L to 5.9 mmol/L (central or 
local laboratory); and 
o Severe hyperkalemia defined as serum potassium  6.0 mmol/L; 
• Reduction from Day 1 eGFR levels  30% throughout the duration of the study; 
• Hypertensive emergency;  
o  Defined as confirmed (based on the mean of at least 2 current consecutive 
protocol-required blood pressure readings, or otherwise obtained blood pressure readings) 
with SBP > 180 mmHg and/or DBP > 120 mmHg with associated new or progressive target 
organ damage, neurologic, and/or cardiac symptoms. Blood pressures of > 200 mmHg in 
asymptomatic patients should be recorded in the eCRF, and Investigators must differentiate 
between hypertensive urgency (markedly elevated blood pressure) and emergency. See 
Section 8.14 and Appendix C for definition and management of hypertensive emergencies 
and urgencies; and  
• Symptomatic hypotension, or if the SBP < 90 mmHg after the first dose of study drug at Day 1. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
67 
8.3 
Serious Adverse Events 
An adverse event or adverse reaction is considered serious if, in the view of either the Investigator 
or Sponsor, it results in any of the following outcomes: 
• Death, 
• A life-threatening adverse event, 
o Note: An adverse event or adverse reaction is considered “life-threatening” if, in view of 
either the Investigator or Sponsor, its occurrence places the patient at immediate risk of 
death. It does not include an event that, had it occurred in a more severe form, might have 
caused death. 
• Requires hospitalization or prolongation of existing hospitalizations, 
o Note: Any hospital admission with at least 1 overnight stay will be considered an inpatient 
hospitalization. An emergency room visit without hospital admission will not be recorded 
as an SAE under this criterion, nor will hospitalization for a procedure scheduled or 
planned before signing of informed consent. However, unexpected complications and/or 
prolongation of hospitalization that occur during elective surgery should be recorded as 
adverse events and assessed for seriousness. Admission to the hospital for social or 
situational reasons (ie, no place to stay, live too far away to come for hospital visits) will 
not be considered inpatient hospitalizations.  
• A persistent or significant disability/incapacity or substantial disruption of the ability to 
conduct normal life functions, 
• A congenital anomaly/birth defect, or 
• An important medical event. 
o Note: Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered an SAE when, based upon appropriate medical 
judgment, they may jeopardize the patient and may require medical or surgical intervention 
to prevent one of the outcomes listed above. Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, 
blood dyscrasias or convulsions that do not result in inpatient hospitalizations, or the 
development of drug dependency. 
8.4 
Serious Adverse Event Reporting − Procedures for Investigators 
Initial Reports 
All SAEs occurring from the time of informed consent until 30 days following the last 
administration of study drug must be reported to Worldwide Drug Safety within 24 hours of the 
knowledge of the occurrence (this refers to any adverse event that meets any of the aforementioned 
serious criteria). All SAEs that the Investigator considers related to study drug occurring after the 
30-day follow-up period must be reported to the Sponsor. 
To report the SAE, complete the SAE form electronically in the electronic data capture (EDC) 
system for the study. When the form is completed, Worldwide Drug Safety personnel will be 
notified electronically and will retrieve the form. If the event meets serious criteria and it is not 
possible to access the EDC system, contact Worldwide Drug Safety by email or phone, and fax 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
68 
the completed paper SAE form (e-mail address and phone and fax numbers listed below) within 
24 hours of awareness. When the EDC system becomes available, the SAE information must be 
entered within 24 hours. 
• Safety Contact Information: Site staff will complete the paper SAE report form and e-mail 
it within 24 hours to the following address: drugsafety@worldwide.com. 
• In cases where the email system is unavailable, site staff will send the SAE by fax to: 
+1-866-387-5539 (US) and +44 208 043 4813 (ROW). 
 
Follow-Up Reports 
The Investigator must continue to follow the patient until the SAE has subsided or until the 
condition becomes chronic in nature, stabilizes (in the case of persistent impairment), or the patient 
dies. 
Within 24 hours of receipt of follow-up information, the Investigator must update the SAE form 
electronically in the EDC system for the study and submit any supporting documentation 
(eg, patient discharge summary or autopsy reports) to Worldwide Drug Safety via fax or e-mail. If 
it is not possible to access the EDC system, refer to the procedures outlined above for initial 
reporting of SAEs.  
8.5 
Pregnancy Reporting 
If the patient or partner of a patient participating in the study becomes pregnant during the study 
or within 90 days of discontinuing study drug, the Investigator should report the pregnancy to 
Worldwide Drug Safety within 24 hours of being notified. Worldwide Drug Safety will then 
forward the Exposure In Utero form to the Investigator for completion.  
A patient becoming pregnant while on study drug will immediately be withdrawn from the study 
and early termination study procedures will be performed. 
The patient or partner should be followed by the Investigator until completion of the pregnancy. 
If the pregnancy ends for any reason before the anticipated date, the Investigator should notify 
Worldwide Clinical Safety. At the completion of the pregnancy, the Investigator will document 
the outcome of the pregnancy. If the outcome of the pregnancy meets the criteria for immediate 
classification as an SAE (ie, postpartum complication, spontaneous abortion, stillbirth, neonatal 
death, or congenital anomaly), the Investigator should follow the procedures for reporting an SAE. 
8.6 
Expedited Reporting 
The Sponsor will report all relevant information about suspected unexpected serious adverse 
reactions in accordance with International Council for Harmonisation (ICH) for Good Clinical 
Practices, Food and Drug Administration (FDA) guidelines, Directive 2001/20/EC of the European 
Parliament and the CT3 Guideline, and any other local regulations applicable in the participating 
countries.  
The Sponsor or designee will also inform all Investigators as required. When required due to local 
regulations, the Investigator will provide expedited reports to the Institutional Review 
Board (IRB)/Independent Ethics Committees (IECs). 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
69 
8.7 
Clinical Laboratory Evaluations 
Detailed procedures of sampling preparation, storage, and shipment will be described in a specific 
laboratory manual, which will be provided to all sites. The visits at which these samples will be 
collected are shown in the Schedule of Procedures (Appendix A) and the data captured will be 
forwarded to the central laboratory for evaluation, unless otherwise specified. See Appendix B for 
a list of clinical laboratory analytes to be measured.  
The Investigator should review and evaluate out of range laboratory results. Any clinically relevant 
abnormal laboratory value should be immediately rechecked whenever possible, for confirmation 
before making any decision for the concerned patient. It should be documented as an adverse 
event/SAE as applicable. 
8.8 
Vital Signs 
Vital signs include pulse rate, respiratory rate, and oral temperature. Vital signs will be assessed 
at the visits indicated on the Schedule of Procedures (Appendix A). Triplicate blood pressure 
should be taken approximately 2 minutes apart with the patient in the seated position and having 
rested for at least 10 minutes prior to assessment. Blood pressure and pulse rate will be measured 
at the same time. 
8.9 
Electrocardiograms 
A 12-lead ECG will be performed in triplicate at the visits indicated on the Schedule of Procedures 
(Appendix A). Patients should be resting in the supine position for at least 10 minutes prior to the 
assessment. The Investigator will assess ECG data as normal, abnormal not clinically significant, 
or abnormal clinically significant. Any clinically significant abnormalities should be documented 
as an adverse event/SAE as applicable. All ECG traces will be kept as source data. 
8.10 
Physical Examinations 
The Investigator or a licensed study team member, per local regulations, will perform physical 
examinations according to the Schedule of Procedures (Appendix A). Physical examinations will 
evaluate the following body systems/organs: general appearance; dermatological; head and eyes; 
ears, nose, mouth, and throat; pulmonary; cardiovascular; abdominal; genitourinary (optional); 
lymphatic; musculoskeletal/extremities; and neurological. If a system is not assessed, the 
Investigator or designee will note the reason in the source documents. If a new clinically significant 
abnormality or worsening from baseline is detected after randomization, then an adverse event 
should be reported and the patient should be considered for further clinical investigations and/or 
specialist consultation as per the Investigator’s medical judgment. 
8.11 
Height, Weight, and Body Mass Index 
Height will be measured at Screening only. Weight will be measured at the visits indicated in the 
Schedule of Procedures (Appendix A). Body mass index will be calculated and recorded at 
Screening and at Day 84. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
70 
8.12 
Safety Surveillance and Management of Serum Potassium Levels 
Serum potassium levels of study patients will be monitored systematically throughout the study. 
In addition to the clinical laboratory tests pre-defined in the Schedule of Procedures (Appendix A), 
unscheduled assessments of serum potassium levels are recommended under certain situations 
(eg, vomiting and/or diarrhea for  1 day) that may impact patients’ serum electrolyte levels or 
fluid balance. 
In patients with serum potassium above the normal laboratory reference range (serum potassium 
levels  5.0 mmol/L), it is advised that the Investigator should reinforce dietary restriction for 
management of elevated potassium and consider local guideline recommendations. Table 1 below 
summarizes the laboratory testing for assessment of serum potassium levels  5.0 mmol/L and 
guidelines for management of study drug, which includes continuation thereof, holding of study 
drug, and/or discontinuation of study drug. If serum potassium levels are < 5.0 mmol/L, no action 
is indicated. A serum potassium level of  5.6 mmol/L requires a hold of study drug and 
appropriate retesting and intervention as described in Table 1. A potassium level of  6.0 mmol/L 
necessitates immediate and permanent discontinuation of study drug.  
Because of potential issues anticipated from routine sample handling and extended transportation 
time to the central laboratory, pseudohyperkalemia secondary to hemolysis may occur in centrally 
analyzed laboratory samples. For this reason, during treatment with study drug, all serum 
potassium assessments, including retests, will be performed at both local and central laboratories. 
In general, if the initial local and/or central laboratory test shows that a patient’s serum potassium 
level is  5.3 mmol/L, a repeat local test is required to confirm elevation of serum potassium levels 
and dictate actions to be taken as outlined in Table 1. All samples should be screened for hemolysis 
to eliminate the possibility of pseudohyperkalemia. Results from the central laboratory will be 
used for data analysis. If a major discrepancy exists between the local and central laboratory 
values, defined as a ±0.3 mmol/L difference between values or if hemolysis is noted in the 
specimens, repeat blood samples should be obtained to confirm eligibility or continuation in the 
study. Again, decisions to enroll or randomize a patient should generally be based on the local 
serum potassium. However, if the central laboratory serum potassium is  4.8 mmol/L and the 
local potassium test is > 4.8 mmol/L, the more conservative value may be used if the difference 
between the 2 samples is  0.3 mmol/L.10 
Serum potassium recheck is recommended within 24, 48, or 72 hours, depending on the level of 
hyperkalemia, following Investigator notification of a serum potassium  5.3 mmol/L (see 
Table 1). The Investigator can perform additional serum potassium retests when clinically 
indicated for medical conditions or procedures that occur during the study. Blood samples should 
be obtained atraumatically, without fist clenching or prolonged use of a tourniquet. 
Non-hemolyzed blood samples sent for rechecks or retests will be analyzed in both local and 
central laboratories. In some circumstances, as outlined below in Table 1, a second retest may be 
indicated and should be performed within 1 week to allow the patient to adjust to the withdrawal 
of study drug (if indicated) and application of standard of care. All episodes of hyperkalemia, 
serum potassium of > 5.0 mmol/L should be reported as an adverse event of special interest. 
The monitoring of serum potassium and the decision on whether or not to discontinue study drug, 
as well as other interventions, are outlined in Table 1. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
71 
Table 1. Potassium Safety Monitoring – Reporting / Management of Hyperkalemia  
 
Alert Local and Central Laboratory Serum Potassium (K+) Values 
> 5.0 to 5.2 mmol/L 
5.3 to 5.5 mmol/L 
5.6 to 5.9 mmol/L 
 6.0 mmol/L 
Following notification 
of a serum K+ alert 
value1 
 
Contact patient and schedule repeat 
serum K+ within 24-72 hours after 
laboratory notification. 
Contact patient and schedule repeat 
serum K+ within 24-48 hours after 
laboratory notification. 
Contact patient and schedule repeat 
serum K+ within 24 hours after 
laboratory notification. 
Management  
Continue study drug. 
Continue study drug pending retest 
results. 
Hold study drug pending retest results. 
Permanently discontinue study 
drug. 
Treatment 
Reinforce low K+ 
diet.  
Reinforce low- K+ diet; manage HK per 
local SOC (no K+ binders). 
Reinforce low- K+ diet; manage HK per 
local SOC (no K+ binders). 
Reinforce low- K+ diet; manage HK 
per local SOC (may use K+ binders)..  
If first serum K+ retest 
is < 5.3 mmol/L 
Continue study drug.  
Resume study drug.  
 
 
 
 
 
Note: Following discontinuance of 
study drug continue study visits and 
safety monitoring.  
 
 
 
 
 
 
 
 
Report as AE as Special Interest 
Management following 
first serum K+ retest 
If retest serum K+ is  5.3 to 
5.5 mmol/L: 
1. 
Hold study drug,  
2. 
Consider higher dose of diuretic,  
3. 
Schedule second serum K+ retest 
within 1 week. 
If retest serum K+ > 5.5 mmol/L, 
permanently discontinue study drug. 
If retest serum K+ is  5.3 to 
5.5 mmol/L: 
1. 
Continue to hold study drug,  
2. 
Consider higher dose of diuretic,  
3. 
Schedule second serum K+ retest 
within 1 week.  
If retest serum K+ > 5.5 mmol/L, 
permanently discontinue study drug.  
Management following 
second serum K+ retest 
If serum K+ on retest is < 5.3 mmol/L, 
continue study drug. 
 
If serum K+ on retest is 
 5.3 mmol/L, permanently 
discontinue study drug. 
If serum K+ is < 5.3 mmol/L, resume 
study drug.  
 
If serum K+ on retest is  5.3 mmol/L, 
permanently discontinue study drug.  
Adverse Event 
Reporting 
Report as AE of Special Interest 
Report as AE of Special Interest 
1 
In the absence of hemolysis, the more conservative value from the central or local laboratories should be used to guide management and treatment 
 
Study sites should make repeated attempts to contact patients with high K+ or HK to ensure compliance with K+ safety monitoring and required retests. 
 
If the serum K+ levels are  5.3 mmol/L, repeat local and central serum K+ testing is required in compliance with the above management strategies and procedures  
 
The Investigator should consider local guideline and SOC for management of serum potassium levels above the normal laboratory reference range. In all instances, dietary 
restriction for management of elevated potassium should be reinforced. Consider use of higher dose of loop or thiazide like diuretics to manage HK. If chronic or 
intermittent treatment with potassium-binders is required, the patient should be permanently discontinued from study drug.  
 
If the locally analyzed blood sample is missing, or the result is inconclusive, another blood sample should be taken as soon as possible but no later than 24 to up to 72 
hours to confirm the value. 
 
The Sponsor or delegate will be notified by site personnel within 24 hours of the site being aware of results for any local laboratory potassium value ( 5.3 mmol/L). 
Retest/confirmatory testing results will be forwarded to the Sponsor or delegate within 24 hours of the site being aware of results. 
Abbreviations: K+: potassium, HK: hyperkalemia, SOC: Standard of care. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
72 
Regardless of whether a patient will discontinue study drug due to elevated serum potassium 
levels, he/she should be closely monitored and treated, as appropriate, per the Investigator’s 
assessment.  
8.13 
Safety Management of Serum Creatinine 
Serum creatinine may increase, at least temporarily, with the initiation of MRA treatment, 
especially in patients with more advanced CKD, most likely reflecting hemodynamic alterations. 
Therefore, serum creatinine will be measured at baseline and closely monitored systematically 
throughout this Phase 2 study. Study drug will be discontinued permanently if serum creatinine 
increases  50% from baseline during the study treatment period. 
8.14 
Monitoring and Management of Blood Pressure 
Blood pressure will be closely monitored throughout this study. At Screening, patients must have 
uncontrolled hypertension, defined as resting trough-cuff seated SBP  140 and  179 mmHg 
based on the mean of at least 2 current consecutive blood pressure readings at Screening and the 
end of the run-in period in the clinic. Blood pressures are obtained according to the AHA 
recommendations for accurate blood pressure measurement. Patients should avoid smoking, 
caffeine, or exercise within 30 minutes before measurement; empty his or her bladder; then sit 
quietly in a comfortable chair with back support for at least 10 minutes before a measurement; and 
remain still during the measurement. The patient’s limb should be supported to measure blood 
pressure and ensure that the blood pressure cuff is at heart level, using the correct cuff size. Do not 
take the measurement over clothes. Blood pressure measurements should be performed in the same 
arm throughout the study. Measurement will be taken with a validated, oscillometric upper arm 
blood pressure monitor. 
In all cases, dose and frequency of concurrent antihypertensive medications are expected to be 
maintained without change for 30 days prior to randomization. In general, patients should not add 
or adjust dose and/or types of the antihypertensive medications they are receiving during the 
screening period and throughout the duration of the study (unless they develop symptomatic 
hypotension). The dose of diuretic may be adjusted based on developing or resolved edema, weight 
gain or loss, or pulmonary congestion. Antihypertensive therapy may be modified if necessary 
during the safety assessment, following withdrawal of the study drug to maintain blood pressure 
control.  
Diagnoses of hypertensive emergency require discontinuance of the study drug, and immediate 
treatment per local treatment guidelines. The occurrence of hypertensive urgency or a transient 
severe elevation in blood pressure may or may not require removal of a patient from the study drug 
but should be recorded as an adverse event and reviewed with the study Medical Monitor. 
AHA/American College of Cardiology definitions, clinical definitions, and treatment algorithms 
for hypertensive emergency, hypertensive urgency, or marked elevations in blood pressure appear 
in Appendix C. 
Symptomatic hypotension or a confirmed trough-seated SBP < 90 mmHg based on the mean of at 
least 2 current consecutive protocol-required blood pressure readings, or otherwise obtained blood 
pressure reading) after the first dose of study drug at Day 1, should be reported as an adverse event 
of special interest. Investigators should evaluate and correct any potential reasons that may 
contribute to hypotension, such as dehydration, decreased blood volume, potential overdose of 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
73 
antihypertensive medication (including study drugs), etc. If symptomatic hypotension or a 
confirmed trough-seated SBP < 90 mmHg occurs, Investigators may consider down-titration of 
antihypertensive medications (other than study drug) first. If symptomatic hypotension or a 
confirmed trough-seated SBP < 90 mmHg persists following down titration study drug should be 
permanently discontinued. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
74 
9 
STATISTICS 
9.1 
Analysis Populations 
The Intent-to-Treat (ITT) Population will consist of all randomized patients who take at least 
1 dose of randomized study drug, have a baseline SBP measurement, and have at least 
1 post-randomization SBP measurement. The ITT Population is the primary analysis population. 
All efficacy analyses will be performed for the ITT Population. 
The Per-Protocol Population will include all ITT patients who have completed the 84-day 
double-blind treatment period without any major protocol deviations or violations. The 
Per-Protocol Population will be used to assess robustness of the primary analysis results. The major 
protocol deviations will be pre-specified prior to unblinding treatment codes for analyses. 
The Safety Population will include all randomized patients who receive at least 1 dose of 
randomized study drug. 
The PPK Population will include all randomized patients who receive at least 1 dose of randomized 
study drug and have at least 1 measurable concentration of total KBP-5074. 
9.2 
Statistical Methods 
9.2.1 
Demographic and Baseline Comparability 
Patient disposition and analysis population data will be tabulated by treatment group with number 
and percentage of patients. Summary statistics will be provided by treatment group for 
demographics (eg, age, sex, race, and ethnicity) and for baseline efficacy variables (such as SBP, 
serum potassium, eGFR, creatinine, DBP, and UACR). For efficacy variables, baseline will be 
defined as the Day 1 (Visit 4) measurement. If the measurement at this visit is missing, then the 
last measurement prior to the first dose of randomized study drug will be used. 
9.2.1.1 
Study drug exposure, compliance, and concomitant therapies 
Overall percent compliance to study drug dosage regimen, calculated as percent of doses taken 
relative to doses scheduled to be taken, will be summarized by treatment group. Extent of exposure 
in days will be evaluated and summarized from the first dose date to the last dose date of 
randomized study drug. 
Concomitant medication/therapy verbatim terms will be coded using the latest version of the 
World Health Organization Drug Dictionary. The number and percentage of patients taking new 
concomitant medications after first dose date will be summarized by Anatomic Therapeutic 
Chemical classification and preferred term for each treatment group. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
75 
9.2.2 
Analysis of Efficacy 
9.2.2.1 
Primary efficacy analysis 
The primary efficacy analysis is to evaluate the change in trough-cuff seated SBP from baseline to 
Day 84 for the KBP-5074 doses compared to placebo. The endpoint for each patient is defined as 
the Day 84 cuff seated SBP measurement. If the measurement at this visit is missing or the patient 
discontinues early, the last post-baseline measurement during the double-blind period will be used. 
The primary efficacy analysis will be carried out using a 2-way analysis of covariance (ANCOVA) 
model with treatment, baseline eGFR level ( 30 versus < 30 mL/min/1.73 m2), and background 
antihypertensive medication (2 or more) as factors, and the baseline SBP value as a covariate. The 
least-squares means, standard errors, and the 2-tailed 95% confidence intervals (CIs) for each 
treatment group and for the comparison will be estimated. The treatment difference between 
KBP-5074 doses and placebo will be estimated from the ANCOVA model. No multiple 
comparison adjustment will be used for this Phase 2 study. 
The primary efficacy analysis will be based on the ITT Population. Other imputation methods for 
the primary efficacy endpoint will be explored. The supportive analysis will be carried out for the 
primary efficacy variable based on the Per-Protocol Population to examine the impact due to 
premature dropouts and/or major protocol deviations or violations. 
9.2.2.2 
Secondary efficacy analyses 
For continuous secondary efficacy variables, the same ANCOVA model will be used as the 
primary efficacy analysis. For categorical data, logistic regression or chi-square test will be used. 
Treatment effects will be evaluated between KBP-5074 doses and placebo. 
9.2.3 
Analysis of Safety 
The assessment of safety will be based primarily on the frequency of patients with adverse events 
and clinical laboratory abnormalities. Other safety data will be summarized as appropriate. 
All safety analyses will be conducted on the total patient cohort based on the Safety Population. 
Adverse events will be coded using the Medical Dictionary for Regulatory Activities. Reports will 
be provided to the Medical Monitor for approval of the coded terms after the database is clean, 
prior to unblinding. The number and frequency of patients with TEAEs (ie, those adverse events 
that newly occur or worsen in severity during the study) will be summarized by system organ class 
and preferred term. Serious adverse events and TEAEs related to study drug will be summarized 
in the same manner. A list of patients with SAEs and those who discontinue from the study due to 
an adverse event will be provided. 
Summary statistics by treatment group at baseline, at all post-randomization visits, and changes 
from baseline to the post-randomization visits for laboratory values will be provided. Occurrence 
of significant abnormalities in laboratory values from baseline will be summarized by treatment 
group. Vital signs, body weight, and physical examination findings will be summarized. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
76 
9.2.4 
Analysis of Pharmacokinetics 
The analysis of the PK/PD relationship will be explored. Population PK models will be built using 
a nonlinear mixed effects modeling technique with NONMEM software based on the PPK 
Population. Different PK models will be attempted to fit the PK concentration-time data. After the 
PPK modeling, a population PD approach will be used to explore the concentration-effect 
relationships. Different PD models will be attempted to fit the concentration-effect data. All PD 
exploration will be based on the ITT Population. 
9.2.5 
Interim Analysis 
No interim analysis is planned. 
9.2.6 
Independent Data Monitoring Committee 
An IDMC will be utilized in this study. The committee will consist of members external to 
Worldwide and KBP BioSciences. The objective of the committee is to monitor safety data on an 
ongoing basis. The approved IDMC charter will be on file and available for inspection as 
requested.  
Meeting Schedule 
After the organizational meeting, the IDMC will meet at least 4 times during the conduct of the 
study at the following treatment milestones: 
• Approximately 10% of patients completed are randomized in the study,  
• Approximately 25% of patients completed the 12-week treatment period,  
• Approximately 50% of patients completed the 12-week treatment period, and 
• Approximately 75% of patients completed the 12-week treatment period.  
The analysis for the IDMC report will be conducted by an independent group not involved with 
the study conduct. A blinded summary of all adverse events and SAEs will be provided every 
4 weeks to the IDMC and the Sponsor for ongoing safety data monitoring. 
No formal inferential hypothesis testing will be conducted from the interim. The study will not 
stop early based on interim efficacy findings. Therefore, no further multiple testing adjustments 
nor any sample size adjustments will be implemented for the final analysis CIs. 
9.2.7 
Sample Size Determination 
For this Phase 2 study, the primary efficacy endpoint is the change in trough-cuff resting seated 
SBP from baseline to Day 84. Assuming an observed treatment difference of SBP changes between 
the KBP-5074 group and the placebo group is 5 mmHg, and a standard deviation of change from 
baseline of 15 mmHg, with 80 patients/group, the CI of the observed difference would not 
include 0. Assuming 10% to 15% dropout post randomization, 80 patients/group or a total of 
240 patients would be needed for this Phase 2 study. Additional sample size estimates based on 
sample size needed per group to ensure that the observed 95% CI does not include 0 are shown in 
Table 2. No multiple comparison adjustment will be applied. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
77 
Table 2. Sample Size Estimates 
Standard Deviation 
Observed Treatment Effect 
4 mmHg 
5 mmHg 
6 mmHg 
14 mmHg 
109 
70 
48 
15 mmHg 
125 
81 
56 
16 mmHg 
141 
91 
63 
Including approximately 10% to 15% dropout. 
Abbreviations: mmHg = millimeters of mercury. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
78 
10 
DATA MANAGEMENT AND RECORD KEEPING 
10.1 
Data Management 
10.1.1 
Data Handling 
Data will be recorded at the site on eCRFs and reviewed by the Clinical Research Associate (CRA) 
during monitoring visits. The CRAs will verify data recorded in the EDC system with source 
documents. All corrections or changes made to any study data must be appropriately tracked in an 
audit trail in the EDC system. An eCRF will be considered complete when all missing, incorrect, 
and/or inconsistent data has been accounted for. 
10.1.2 
Computer Systems 
Data will be processed using a validated computer system conforming to regulatory requirements. 
10.1.3 
Data Entry 
Data must be recorded using the EDC system as the study is in progress. All site personnel must 
log into the system using their secure user name and password in order to enter, review, or correct 
study data. These procedures must comply with Title 21 of the Code of Federal Regulations 
(21 CFR Part 11) and other appropriate international regulations. All passwords will be strictly 
confidential. 
10.1.4 
Medical Information Coding 
For medical information, the following dictionaries will be used: 
• Medical Dictionary for Regulatory Activities (latest) for medical history and adverse events, 
and 
• World Health Organization Drug Dictionary for prior and concomitant medications. 
10.1.5 
Data Validation 
Validation checks programmed within the EDC system, as well as supplemental validation 
performed via review of the downloaded data, will be applied to the data in order to ensure 
accurate, consistent, and reliable data. Data identified as erroneous, or data that are missing, will 
be referred to the investigative site for resolution through data queries. 
The eCRFs must be reviewed and electronically signed by the Investigator. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
79 
10.2 
Record Keeping 
Records of patients, source documents, monitoring visit logs, eCRFs, inventory of study product, 
regulatory documents, and other Sponsor correspondence pertaining to the study must be kept in 
the appropriate study files at the site. Source data is defined as all information in original records 
and certified copies of original records of clinical findings, observations, or other activities in a 
clinical study necessary for the evaluation and reconstruction of the clinical study. Source data are 
contained in source documents (original records or certified copies). These records will be retained 
in a secure file for the period as set forth in the Clinical Study Agreement. Prior to transfer or 
destruction of these records, the Sponsor must be notified in writing and be given the opportunity 
to further store such records.  

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
80 
11 
INVESTIGATOR REQUIREMENTS AND QUALITY CONTROL  
11.1 
Ethical Conduct of the Study 
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for 
designing, conducting, recording, and reporting studies that involve human patients. Compliance 
with this standard provides public assurance that the rights, safety, and well-being of study patients 
are protected, consistent with the principles that have their origin in the Declaration of Helsinki, 
and that the clinical study data are credible. 
11.2 
Institutional Review Board/Independent Ethics Committee 
The IRB or IEC will review all appropriate study documentation in order to safeguard the rights, 
safety, and well-being of patients. The study will only be conducted at sites where IRB/IEC 
approval has been obtained. The protocol, Investigator’s Brochure, Informed Consent Form (ICF), 
advertisements (if applicable), written information given to the patients, safety updates, annual 
progress reports, and any revisions to these documents will be provided to the IRB/IEC by the 
Investigator. 
Federal regulations and ICH Guidelines require that approval be obtained from an IRB/IEC prior 
to participation of patients in research studies. Prior to study onset, the protocol, any protocol 
amendments, ICFs, advertisements to be used for patient recruitment, and any other written 
information regarding this study to be provided to a patient or patient’s legal guardian must be 
approved by the IRB/IEC. 
No drug will be released to the site for dosing until written IRB/IEC authorization has been 
received by the Sponsor. 
11.3 
Informed Consent 
The ICF and any changes to the ICF made during the course of the study must be agreed to by the 
Sponsor or designee and the IRB/IEC prior to its use and must be in compliance with all ICH GCP, 
local regulatory requirements, and legal requirements.  
The Investigator must ensure that each study patient is fully informed about the nature and 
objectives of the study and possible risks associated with participation and must ensure that the 
patient has been informed of his/her rights to privacy. The Investigator will obtain written informed 
consent from each patient before any study-specific activity is performed and should document in 
the source documentation that consent was obtained prior to enrollment in the study. The original 
signed copy of the ICF must be maintained by the Investigator and is subject to inspection by a 
representative of the Sponsor, their representatives, auditors, the IRB/IEC and/or regulatory 
agencies. A copy of the signed ICF will be given to the patient.  
11.4 
Study Monitoring Requirements 
It is the responsibility of the Investigator to ensure that the study is conducted in accordance with 
the protocol, Declaration of Helsinki, ICH GCP, and applicable regulatory requirements, and that 
valid data are entered into the eCRFs. 
To achieve this objective, the monitor’s duties are to aid the Investigator and, at the same time, the 
Sponsor in the maintenance of complete, legible, well organized and easily retrievable data. Before 
the enrollment of any patient in this study, the Sponsor or their designee will review with the 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
81 
Investigator and site personnel the following documents: protocol, Investigator’s Brochure, eCRFs 
and procedures for their completion, informed consent process, and the procedure for reporting 
SAEs. 
The Investigator will permit the Sponsor or their designee to monitor the study as frequently as 
deemed necessary to determine that data recording and protocol adherence are satisfactory. During 
the monitoring visits, information recorded on the eCRFs will be verified against source 
documents and requests for clarification or correction may be made. After the eCRF data is entered 
by the site, the CRA will review the data for safety information, completeness, accuracy, and 
logical consistency. Computer programs that identify data inconsistencies may be used to help 
monitor the clinical study. If necessary, requests for clarification or correction will be sent to 
Investigators. The Investigator and his/her staff will be expected to cooperate with the monitor and 
provide any missing information, whenever possible. 
All monitoring activities will be reported and archived. In addition, monitoring visits will be 
documented at the investigational site by signature and date on the study-specific monitoring log. 
11.5 
Disclosure of Data 
Data generated by this study must be available for inspection by the FDA, the Sponsor or their 
designee, applicable foreign health authorities, and the IRB/IEC as appropriate. Patients or their 
legal representatives may request their medical information be given to their personal physician or 
other appropriate medical personnel responsible for their welfare. 
Patient medical information obtained during the study is confidential and disclosure to third parties 
other than those noted above is prohibited. 
11.6 
Retention of Records 
To enable evaluations and/or audits from regulatory authorities or the Sponsor, the Investigator 
will keep records, including the identity of all participating patients (sufficient information to link 
records, eg, eCRFs and hospital records), all original signed ICFs, copies of all eCRFs, SAE forms, 
source documents, and detailed records of treatment disposition. The records should be retained 
by the Investigator according to specifications in the ICH guidelines, local regulations, or as 
specified in the Clinical Study Agreement, whichever is longer. The Investigator must obtain 
written permission from the Sponsor before disposing of any records, even if retention 
requirements have been met. 
If the Investigator relocates, retires, or for any reason withdraws from the study, the Sponsor should 
be prospectively notified. The study records must be transferred to an acceptable designee, such 
as another Investigator, another institution, or to the Sponsor.  
11.7 
Publication Policy 
Following completion of the study, the data may be considered for publication in a scientific 
journal or for reporting at a scientific meeting. Each Investigator is obligated to keep data 
pertaining to the study confidential. The Investigator must consult with the Sponsor before any 
study data are submitted for publication. The Sponsor reserves the right to deny publication rights 
until mutual agreement on the content, format, interpretation of data in the manuscript, and journal 
selected for publication are achieved. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
82 
11.8 
Financial Disclosure 
Investigators are required to provide financial disclosure information to the Sponsor to permit the 
Sponsor to fulfill its obligations under 21 CFR Part 54. In addition, Investigators must commit to 
promptly updating this information if any relevant changes occur during the study and for a period 
of 1 year after the completion of the study. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
83 
12 
STUDY ADMINISTRATIVE INFORMATION 
12.1 
Protocol Amendments 
Any amendments to the study protocol will be communicated to the Investigators by Worldwide 
or the Sponsor. All protocol amendments will undergo the same review and approval process as 
the original protocol. A protocol amendment may be implemented after it has been approved by 
the IRB/IEC, unless immediate implementation of the change is necessary for patient safety. In 
this case, the situation must be documented and reported to the IRB/IEC within 5 working days. 
12.2 
Address List 
12.2.1 
Sponsor 
KBP BioSciences Co., Ltd. 
116 Village Blvd, Suite 210 
Princeton, NJ 08540 
United States 
Telephone: +1-609-531-0889 
Fax: +1-609-531-0892 
12.2.2 
Contract Research Organization 
Worldwide Clinical Trials 
3800 Paramount Parkway 
Suite 400 
Morrisville, NC 27560 
United States 
Telephone: +1 610-964-2000 
12.2.3 
Drug Safety 
Worldwide Clinical Trials 
3800 Paramount Parkway 
Suite 400 
Morrisville, NC 27560 
United States 
 
Worldwide Clinical Trials SAE reporting line: 
Fax: +1-866-387-5539 (US) and +44 208 043 4813 (ROW). 
e-mail: drugsafety@worldwide.com 
12.2.4 
Biological Specimens 
Central Laboratory 
Contact information provided separately to sites. 
 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
84 
Central Laboratory (For PK Samples Only) 
Contact information provided separately to sites. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
85 
13 
REFERENCES 
 
1. Chatterjee S, Moeller C, Shah N, et al. Eplerenone is not superior to older and less 
expensive aldosterone antagonists. Am J Med. 2012 Aug;125(8):817-825. 
2. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce 
proteinuria in patients with chronic renal disease. N Engl J Med. 
2001 Sep 20;345(12):925-926. 
3. Togawa A, Miyoshi J, Ishizaki H, et al. Progressive impairment of kidneys and 
reproductive organs in mice lacking Rho GDIalpha. Oncogene. 
1999 Sep 23;18(39):5373-5380. 
4. Williams GH, Burgess E, Kolloch RE, et al. Efficacy of eplerenone versus enalapril as 
monotherapy in systemic hypertension. Am J Cardiol. 2004 Apr 15;93(8):990-996. 
5. Brown NJ. Eplerenone: cardiovascular protection. Circulation. 
2003 May 20;107(19):2512-2518. 
6. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone 
blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002 Aug;15(8):709-716. 
7. KBP-5074 Investigator’s Brochure Fifth Edition, dated 21 April 2018. 
8. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal 
Disease Study equation for estimating glomerular filtration rate with standardized serum 
creatinine values. Clin Chem. 2007 Apr;53(4):766-772. 
9. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management 
of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. 
10. Friedman PA, Scott CG, Bailey K, et al. Errors of classification with potassium blood 
testing: the variability and repeatability of critical clinical tests. Mayo Clin Proc. 
2018 May;93(5):566-572. 
 
 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
86 
APPENDIX A:  SCHEDULE OF PROCEDURES 
Study Period 
Screening1 
( 4 
weeks) 
Open-Label 
Placebo Run-In 
(2 weeks) 
 
Double-Blind Treatment 
EOS 
ET2 
Study Day 
 -42 days 
 -18 
 -4 
-1 
1 
7 
14 
28 
40 
42 
56 
82 
84 
112 
 
Visit 
1 
2 
3 
ABPM3,4 
45 
5 
6 
7 
ABPM4 
8 
9 
ABPM4 
10 
11 
 
Visit Window 
 
 
 
 
±2 days 
±3 days 
±5 days 
 
Assessment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signed informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eligibility assessment 
X 
 
X 
 
X 
 
 
 
 
 
 
 
 
 
 
Randomization 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical examination 
X 
 
 
 
X6 
 
 
 
 
 
 
 
X 
X 
X 
Height (cm) 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight (kg) 
X 
X 
X 
 
X 
X 
X 
X 
 
X 
X 
 
X 
X 
X 
Body mass index 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
Contact IRT  
X 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
 
X 
Triplicate standard 12-lead ECG7 
X 
 
 
 
X 
X 
 
 
 
 
 
 
 
X 
X 
Vital signs (PR, RR, OT)8 
X 
X 
X 
 
X 
X 
X 
X 
 
X 
X 
 
X 
X 
X 
Blood pressure8,9 
X10 
X 
X10 
 
X11 
X11 
X11 
X11 
 
X11 
X11 
 
X 
X 
X 
24-hour ABPM device placement 
and start4,12 
 
 
 
X 
 
 
 
 
X 
 
 
X 
 
 
 
24-hour ABPM download at site4 
 
 
 
 
X 
 
 
 
 
X 
 
 
X 
 
X13 
HIV, HbsAg, and HCV 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine drug screen 
X 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical laboratory samples 
(central laboratory)14 
X 
 
X15 
 
X 
X 
X 
X 
 
X 
X 
 
X 
X 
X 
Serum potassium (local and 
central laboratories)16 
X 
 
X 
 
X 
X 
X 
X 
 
X 
X 
 
X 
X 
X 
Serum creatinine (central 
laboratory) 
X 
 
X 
 
X 
X 
X 
X 
 
X 
X 
 
X 
X 
X 
Pregnancy test on WOCBP only17 
X 
 
 
 
X 
 
 
 
 
 
 
 
 
X 
X 
FSH18 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum samples for aldosterone 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
X 
Plasma samples for renin 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
X 
Serum and plasma samples for 
additional biomarkers19 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
X 
Plasma samples for PK 
 
 
 
 
X20 
 
X21 
X21 
 
 
 
 
 
X 
X 
Urine samples for UACR 
X 
 
 
 
X 
X 
X 
X 
 
X 
X 
 
X 
X 
X 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
87 
Study Period 
Screening1 
( 4 
weeks) 
Open-label 
Placebo Run-In 
(2 weeks) 
 
Double-Blind Treatment 
EOS 
ET2 
Study Day 
 -42 days 
 -18 
 -4 
-1 
1 
7 
14 
28 
40 
42 
56 
82 
84 
112 
 
Visit 
1 
2 
3 
ABPM3,4 
45 
5 
6 
7 
ABPM4 
8 
9 
ABPM4 
10 
11 
 
Visit Window 
 
 
 
 
±2 days 
±3 days 
±5 days 
 
Provide 24-hour urine collection 
instruction and supplies 
 
 
X 
 
 
 
 
X 
 
 
X 
 
 
 
 
24-hour urine samples for UACR 
 
 
 
 
X 
 
 
 
 
X 
 
 
X 
 
 
Adverse event and concomitant 
medications 
X 
X 
X 
 
X 
X 
X 
X 
 
X 
X 
 
X 
X 
X 
Study drug instruction and 
dispensing 
 
X22 
 
 
X 
X 
X 
X 
 
X 
X 
 
 
 
 
Administer first/daily dose and 
record time 
 
 
 
 
X23 
X24 
X24 
X24 
 
X24 
X24 
 
 
 
 
Study drug accountability and 
collection of unused study drug 
 
 
X25 
 
 
X 
X 
X 
 
X 
X 
 
X 
 
X 
1. 
If a patient is found to be not eligible during Screening, a single rescreening is allowed if the Investigator believes that the patient’s condition has changed, and the patient 
may be eligible before the rescreening tests. 
2. 
The Early Termination Visit should be scheduled only for patients who discontinue the study prematurely; assessments should be performed as early as feasible after 
discontinuation of study drug. 
3. 
This visit is to be scheduled within 3 days after the end of the run-in period (Visit 3) for patients undergoing 24-hour ABPM. 
4. 
This visit/procedure is for patients undergoing 24-hour ABPM only (a subset of up to 40 patients per treatment group who agree to participate in 24-hour ABPM and still 
meet eligibility criteria at the end of the run-in period [Visit 3]). 
5. 
This visit is to be scheduled within 4 ±2 days after the end of the run-in period (Visit 3). 
6. 
A physical examination will be performed pre-dose. 
7. 
Patients should be resting in a supine position for at least 10 minutes prior to assessment. 
8. 
Blood pressure and PR will be measured at the same time. 
9. 
Triplicate blood pressure measurements should be taken approximately 2 minutes apart with a validated, oscillometric upper arm blood pressure monitor with the 
patient in the seated position and having rested for at least 10 minutes prior to assessment. Trough-cuff SBP and DBP values will be assessed based on the 
pre-defined blood pressure measurement guideline throughout the study. 
10. At Screening and the end of the placebo run-in period (Visit 3), patients must have uncontrolled hypertension, defined as resting trough-cuff seated SBP  140 mmHg and 
 179 mmHg based on the mean of at least 2 current consecutive blood pressure readings in the clinic. 
11. Blood pressure must be measured prior to study drug administration. 
12. Blood pressure and heart rate measurements will be obtained every 20 minutes during the interval of 06:00:00 hours to 21:59:59 hours (to coincide with the daytime, 
awake period), and every 30 minutes during the interval of 22:00:00 hours to 05:59:59 hours (to coincide with the nighttime, sleeping period). During the 24-hour ABPM 
recording period, a diary will be provided to the patient. Instructions and training will be provided to the site staff, who will in turn provide instructions to the patient. 
13. If a patient has completed the 24-hour ABPM recording since their last visit, 24-hour ABPM data will be downloaded at the site during the ET Visit. 
14. Clinical laboratories include chemistry, hematology, coagulation, and urinalysis. See Appendix B for the complete list of clinical laboratory analytes assessed for this 
study. 
15. Only clinical chemistry will be conducted at the end of run-in period (Visit 3). 
16. All patients must have a serum potassium  4.8 mmol/L at both Screening and the end of the placebo run-in period (Visit 3). 
17. Serum pregnancy tests will be obtained at Screening, EOS, and ET. A urine pregnancy test will be obtained at pre-dose on Day 1. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
88 
18. Post-menopausal women only. 
19. Serum/plasma samples taken during the study will be stored at a central laboratory for determination of various additional biomarkers, including but not limited to 
galectin-3, N-terminal of the prohormone brain natriuretic peptide, interleukin-6, collagen biomarkers, and C-reactive protein. The panel of biomarkers and time points for 
analysis will be determined prior to the database lock. 
20. Plasma samples are to be collected prior to patient’s discharge from the unit. 
21. Plasma samples are to be collected pre-dose. If patients are not dosed in the unit on those days, a PK sample will be collected, and the date and time of the last dose will be 
recorded. 
22. Open-label placebo will be dispensed at Visit 2. 
23. The first dose of the study drug is to be administered. 
24. The daily dose of the study drug is to be administered. 
25. If a patient’s compliance to medications (including both open-label placebo and current antihypertensive medications) is < 80% or > 120% at Visit 3, he/she will not be 
eligible for the study and no further visits will be performed. 
Abbreviations: ABPM = ambulatory blood pressure monitoring; DBP = diastolic blood pressure; ECG = electrocardiogram; EOS = end of study; ET = early termination;  
FSH = follicle-stimulating hormone; HbsAg = hepatitis B surface antigen; HCV = hepatitis C virus; HIV = human immunodeficiency virus; IRT = Interactive Response 
Technology; OT = oral temperature; PK = pharmacokinetic; PR = pulse rate; RR = respiratory rate; SBP = systolic blood pressure; UACR = urine albumin-to-creatinine ratio; 
WOCBP = women of childbearing potential. 
 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
89 
APPENDIX B:  CLINICAL LABORATORY ANALYTES 
Standard Safety Chemistry Panel 
Alanine aminotransferase 
Albumin 
Alkaline phosphatase 
Amylase 
Aspartate aminotransferase 
Bicarbonate 
Blood urea nitrogen 
Calcium 
Chloride 
Creatine kinase 
Creatinine 
Estimated glomerular filtration rate1 
Gamma-glutamyl transferase 
Glucose 
Inorganic phosphorus 
Lactate dehydrogenase 
Lipase 
Potassium 
Sodium 
Total bilirubin 
Total protein 
Uric acid 
1 
Calculated by the central laboratory using the Modification of Diet in Renal Disease 
equation version 4. 
 
Endocrinology 
Follicle-stimulating hormone (FSH) for post-menopausal women only1 
1 
Post-menopausal is defined as amenorrheic for at least 1 year AND have a serum FSH 
level of > 20 mIU/mL.  
 
Hematology 
Hematocrit 
Hemoglobin 
Platelets 
Red blood cell count 
White blood cell count and differential 
 
 
Urinalysis 
Bilirubin 
Blood 
Glucose 
Ketones 
Leukocyte esterase 
Microscopy1 
Nitrite 
pH 
Protein 
Specific gravity 
Urobilinogen 
 
1 
Microscopy is performed only as needed based on positive dipstick test results. 
 
Additional Urinalysis 
Urine drug screen 
 
Percent change in urine albumin-to-creatinine ratio (UACR) for spot urine specimen 
UACR for 24-hour urine specimen 
 
 
 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
90 
Coagulation 
Activated partial thromboplastin time 
Prothrombin time 
International normalized ratio 
 
 
Serology 
Hepatitis B surface antigen 
Hepatitis C virus 
Human immunodeficiency virus 
 
 
Biomarkers 
Aldosterone 
Renin 
Serum/plasma samples taken during the study will be stored at a central laboratory for 
determination of various additional biomarkers, including but not limited to galectin-3, 
N-terminal of the prohormone brain natriuretic peptide, interleukin-6, collagen biomarkers, 
and C-reactive protein. The panel of biomarkers and time points for analysis will be 
determined prior to the database lock. 
 
Pregnancy Test 
Serum/urine pregnancy tests will be administered to all women patients of childbearing potential. 

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
91 
APPENDIX C:  DEFINITION AND MANAGEMENT OF HYPERTENSIVE 
CRISIS, EMERGENCY, AND URGENCY 
Hypertensive Emergency  
The protocol definition for hypertensive emergency is consistent with that proposed by the 2017 
Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in 
Adults (see Figure 2). In this study, a hypertensive emergency is defined as a confirmed (based on 
the mean of 2 or more consecutive blood pressures readings) severe elevation in systolic blood 
pressure (SBP) > 180 mmHg and/or diastolic blood pressure (DBP) > 120 mmHg in conjunction 
with new or progressive target organ damage (eg, Grade III or IV, etc.), neurologic, or cardiac 
symptoms. Hypertensive emergencies require immediate attention and generally require 
hospitalization in an intensive care unit and the use of parenteral medication for control of blood 
pressure.  
Reduction of blood pressure (not necessarily to normal ranges) is required to prevent or limit 
further target organ damage, which can include, hypertensive encephalopathy, intracranial 
hemorrhage, acute ischemic stroke, acute myocardial infarction, acute left ventricular failure with 
pulmonary edema, unstable angina pectoris, dissecting aortic aneurysm, acute renal failure, and 
eclampsia. 
Selection of a specific agent for blood pressure reduction should be based on a patient’s clinical 
presentation and national or local clinical practice guidelines. In general, autoregulation of tissue 
perfusion is disturbed in hypertensive emergencies; thus, continuous or intermittent infusions of 
short-acting titratable antihypertensive agents is often preferred; use of oral therapy is discouraged 
for hypertensive emergencies.  
It should be noted that hypertensive emergencies in patients presenting with acute intracranial 
hemorrhage and acute ischemic stroke require particularly close management; local guidelines for 
such patients should be followed. Documented hypertensive emergency will require termination 
of the study drug. 
Hypertensive Urgency or Markedly Elevated Blood Pressure  
Confirmed blood pressures where SBP > 180 mmHg and/or DBP > 120 mmHg without 
neurologic, cardiac symptom, or new or progressive hypertensive target organ damage will be 
classified as a hypertensive urgency or markedly elevated blood pressure.  
Management of a hypertensive urgency usually involves reinstitution/intensification of oral 
antihypertensive drug therapy and follow-up. Ideally, blood pressure measurements should be 
repeated approximately every 10 minutes over a 30-minute period in patients with severe 
uncontrolled hypertension, with the patient resting in a quiet, comfortable environment to confirm 
the elevated blood pressure, and to minimize white coat effect, anxiety, stress, pain, etc.  
Hypertensive urgencies are situations associated with severe blood pressure elevation in otherwise 
stable patients without acute or impending change in target organ damage or dysfunction. Many 
of these patients have withdrawn from or are noncompliant with antihypertensive therapy and do 
not have clinical or laboratory evidence of acute target organ damage.  

KBP BioSciences Co., Ltd. 
Clinical Study Protocol KBP5074-2-001 
Confidential & Proprietary 
 
Version 4.0, 16 April 2019 
92 
These patients should not be considered as having a hypertensive emergency and instead are 
treated by reinstitution or intensification of antihypertensive drug therapy and treatment of anxiety 
as applicable. There is no indication for referral to the emergency department, immediate reduction 
in blood pressure in the emergency department, or hospitalization for such patients.  
A documented episode of hypertensive urgency or severe uncontrolled hypertension, pending 
response to drug therapy, may or may not require termination of the study drug. 
Figure 2. Diagnosis and Management of a Hypertensive Crisis  
 
BP = blood pressure; DBP = diastolic blood pressure; h = hour; ICU = intensive care unit; SBP = systolic blood pressure. 
Source: Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/ 
AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood 
Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical 
Practice Guidelines. J Am Coll Cardiol. 07 November 2017; Epub ahead of print.